https://trial.medpath.com/news/aiims-delhi-completes-india-s-first-brain-stent-clinical-trial-achieves-regulatory-approval-for-stroke-treatment 2025-12-13T09:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aiims-delhi-completes-india-s-first-brain-stent-clinical-trial-achieves-regulatory-approval-for-stroke-treatment 2025-12-13T09:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/radiomedix-secures-5-year-thorium-228-supply-deal-to-advance-targeted-alpha-therapy-pipeline 2025-12-13T09:27:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiomedix-secures-5-year-thorium-228-supply-deal-to-advance-targeted-alpha-therapy-pipeline 2025-12-13T09:27:31+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-arpi-data-reinforces-survival-benefits-in-metastatic-prostate-cancer-while-real-world-evidence-gaps-persist 2025-12-13T09:27:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-arpi-data-reinforces-survival-benefits-in-metastatic-prostate-cancer-while-real-world-evidence-gaps-persist 2025-12-13T09:27:06+00:00 hourly 0.9 https://trial.medpath.com/news/sereneuro-s-sn101-pain-sponge-therapy-shows-promise-for-non-opioid-osteoarthritis-treatment 2025-12-13T09:26:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sereneuro-s-sn101-pain-sponge-therapy-shows-promise-for-non-opioid-osteoarthritis-treatment 2025-12-13T09:26:58+00:00 hourly 0.9 https://trial.medpath.com/news/anixa-biosciences-breast-cancer-vaccine-shows-74-immune-response-rate-in-phase-1-trial 2025-12-13T05:29:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anixa-biosciences-breast-cancer-vaccine-shows-74-immune-response-rate-in-phase-1-trial 2025-12-13T05:29:22+00:00 hourly 0.9 https://trial.medpath.com/news/eu-drugs-regulator-backs-higher-dose-of-novo-nordisk-s-wegovy-for-weight-management 2025-12-13T05:27:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-drugs-regulator-backs-higher-dose-of-novo-nordisk-s-wegovy-for-weight-management 2025-12-13T05:27:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-cardamyst-nasal-spray-as-first-self-administered-treatment-for-psvt-in-over-30-years 2025-12-13T05:26:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-cardamyst-nasal-spray-as-first-self-administered-treatment-for-psvt-in-over-30-years 2025-12-13T05:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/tiziana-life-sciences-initiates-phase-2-trial-testing-intranasal-foralumab-for-alzheimer-s-disease-neuroinflammation 2025-12-13T01:31:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tiziana-life-sciences-initiates-phase-2-trial-testing-intranasal-foralumab-for-alzheimer-s-disease-neuroinflammation 2025-12-13T01:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/alphyn-biologics-raises-25m-series-b-to-advance-zabalafin-hydrogel-through-phase-iib-trials-for-atopic-dermatitis 2025-12-13T01:31:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alphyn-biologics-raises-25m-series-b-to-advance-zabalafin-hydrogel-through-phase-iib-trials-for-atopic-dermatitis 2025-12-13T01:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/zelluna-achieves-manufacturing-milestone-for-first-in-class-mage-a4-tcr-nk-cell-therapy 2025-12-13T01:29:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zelluna-achieves-manufacturing-milestone-for-first-in-class-mage-a4-tcr-nk-cell-therapy 2025-12-13T01:29:48+00:00 hourly 0.9 https://trial.medpath.com/news/blood-test-using-ctdna-identifies-colon-cancer-patients-who-benefit-from-celecoxib-anti-inflammatory-therapy 2025-12-13T01:28:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-test-using-ctdna-identifies-colon-cancer-patients-who-benefit-from-celecoxib-anti-inflammatory-therapy 2025-12-13T01:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/edesa-biotech-advances-eb06-anti-cxcl10-antibody-toward-phase-2-vitiligo-trial-in-mid-2026 2025-12-13T01:27:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edesa-biotech-advances-eb06-anti-cxcl10-antibody-toward-phase-2-vitiligo-trial-in-mid-2026 2025-12-13T01:27:09+00:00 hourly 0.9 https://trial.medpath.com/news/canada-s-drug-agency-reports-10-rise-in-drug-submissions-despite-15-drop-in-approvals-for-2024 2025-12-13T01:26:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canada-s-drug-agency-reports-10-rise-in-drug-submissions-despite-15-drop-in-approvals-for-2024 2025-12-13T01:26:34+00:00 hourly 0.9 https://trial.medpath.com/news/circulating-tumor-dna-emerges-as-powerful-prognostic-tool-for-triple-negative-breast-cancer-recurrence-risk 2025-12-12T21:35:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circulating-tumor-dna-emerges-as-powerful-prognostic-tool-for-triple-negative-breast-cancer-recurrence-risk 2025-12-12T21:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/mineralys-therapeutics-lorundrostat-trial-recognized-in-jama-s-inaugural-research-of-the-year-for-treatment-resistant-hypertension 2025-12-12T21:35:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mineralys-therapeutics-lorundrostat-trial-recognized-in-jama-s-inaugural-research-of-the-year-for-treatment-resistant-hypertension 2025-12-12T21:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/tenaya-therapeutics-reports-positive-gene-therapy-data-for-rare-heart-disease-despite-stock-decline-following-60m-offering 2025-12-12T21:34:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenaya-therapeutics-reports-positive-gene-therapy-data-for-rare-heart-disease-despite-stock-decline-following-60m-offering 2025-12-12T21:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/relay-therapeutics-zovegalisib-shows-consistent-efficacy-across-breast-cancer-patient-subgroups-in-sabcs-analysis 2025-12-12T21:33:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/relay-therapeutics-zovegalisib-shows-consistent-efficacy-across-breast-cancer-patient-subgroups-in-sabcs-analysis 2025-12-12T21:33:36+00:00 hourly 0.9 https://trial.medpath.com/news/uc-irvine-receives-12-million-grant-for-first-in-human-huntington-s-disease-stem-cell-trial 2025-12-12T21:31:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-irvine-receives-12-million-grant-for-first-in-human-huntington-s-disease-stem-cell-trial 2025-12-12T21:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/vutrisiran-demonstrates-consistent-cardiovascular-benefits-across-all-age-groups-in-attr-cm-patients 2025-12-12T21:30:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vutrisiran-demonstrates-consistent-cardiovascular-benefits-across-all-age-groups-in-attr-cm-patients 2025-12-12T21:30:45+00:00 hourly 0.9 https://trial.medpath.com/news/sms-pharmaceuticals-passes-usfda-inspection-at-vizag-api-facility-with-minor-observation 2025-12-12T21:30:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sms-pharmaceuticals-passes-usfda-inspection-at-vizag-api-facility-with-minor-observation 2025-12-12T21:30:34+00:00 hourly 0.9 https://trial.medpath.com/news/parse-biosciences-partners-with-tahoe-therapeutics-and-codebreaker-labs-for-massive-single-cell-sequencing-projects 2025-12-12T21:29:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parse-biosciences-partners-with-tahoe-therapeutics-and-codebreaker-labs-for-massive-single-cell-sequencing-projects 2025-12-12T21:29:50+00:00 hourly 0.9 https://trial.medpath.com/news/arcus-and-gilead-discontinue-tigit-therapy-after-phase-iii-gastric-cancer-trial-failure 2025-12-12T21:29:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcus-and-gilead-discontinue-tigit-therapy-after-phase-iii-gastric-cancer-trial-failure 2025-12-12T21:29:32+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-conditional-approval-for-immunitybio-s-anktiva-in-bcg-unresponsive-bladder-cancer 2025-12-12T21:28:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-recommends-conditional-approval-for-immunitybio-s-anktiva-in-bcg-unresponsive-bladder-cancer 2025-12-12T21:28:02+00:00 hourly 0.9 https://trial.medpath.com/news/nimacimab-plus-semaglutide-achieves-superior-weight-loss-in-phase-2a-trial 2025-12-12T17:38:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nimacimab-plus-semaglutide-achieves-superior-weight-loss-in-phase-2a-trial 2025-12-12T17:38:48+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-awaits-pivotal-inz-701-trial-results-following-270m-inozyme-acquisition 2025-12-12T17:36:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarin-awaits-pivotal-inz-701-trial-results-following-270m-inozyme-acquisition 2025-12-12T17:36:21+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-loses-key-patent-protection-for-cancer-drug-cabazitaxel-at-european-court 2025-12-12T17:34:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-loses-key-patent-protection-for-cancer-drug-cabazitaxel-at-european-court 2025-12-12T17:34:51+00:00 hourly 0.9 https://trial.medpath.com/news/sanyou-bio-and-kanrybio-form-strategic-partnership-to-advance-biomarker-assay-kit-development 2025-12-12T17:33:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanyou-bio-and-kanrybio-form-strategic-partnership-to-advance-biomarker-assay-kit-development 2025-12-12T17:33:55+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-sector-sees-record-3-5-billion-fundraising-surge-following-ash-conference 2025-12-12T17:33:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-sector-sees-record-3-5-billion-fundraising-surge-following-ash-conference 2025-12-12T17:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/neuexcell-s-gene-therapy-nxl-004-shows-promising-results-in-first-in-human-trial-for-recurrent-malignant-glioma 2025-12-12T17:33:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuexcell-s-gene-therapy-nxl-004-shows-promising-results-in-first-in-human-trial-for-recurrent-malignant-glioma 2025-12-12T17:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/apremilast-demonstrates-sustained-efficacy-in-moderate-to-severe-genital-psoriasis-through-32-weeks 2025-12-12T17:32:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apremilast-demonstrates-sustained-efficacy-in-moderate-to-severe-genital-psoriasis-through-32-weeks 2025-12-12T17:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/ractigen-therapeutics-initiates-first-in-human-trial-of-rag-18-for-duchenne-muscular-dystrophy 2025-12-12T17:31:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ractigen-therapeutics-initiates-first-in-human-trial-of-rag-18-for-duchenne-muscular-dystrophy 2025-12-12T17:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/peijia-medical-receives-nmpa-approval-for-taurustrio-transcatheter-aortic-valve-system-for-aortic-regurgitation-treatment 2025-12-12T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peijia-medical-receives-nmpa-approval-for-taurustrio-transcatheter-aortic-valve-system-for-aortic-regurgitation-treatment 2025-12-12T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/ema-committee-recommends-expanding-gsk-s-rsv-vaccine-to-all-adults-18-and-over 2025-12-12T17:30:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-committee-recommends-expanding-gsk-s-rsv-vaccine-to-all-adults-18-and-over 2025-12-12T17:30:52+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-drugs-show-16-reduction-in-epilepsy-risk-among-diabetes-patients-in-large-scale-study 2025-12-12T17:30:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-drugs-show-16-reduction-in-epilepsy-risk-among-diabetes-patients-in-large-scale-study 2025-12-12T17:30:49+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-partners-with-taigen-for-ai-driven-anemia-treatment-in-greater-china 2025-12-12T17:30:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insilico-medicine-partners-with-taigen-for-ai-driven-anemia-treatment-in-greater-china 2025-12-12T17:30:47+00:00 hourly 0.9 https://trial.medpath.com/news/ema-approves-seven-new-medicines-including-covid-19-vaccine-and-cancer-treatments 2025-12-12T17:30:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-approves-seven-new-medicines-including-covid-19-vaccine-and-cancer-treatments 2025-12-12T17:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/cytokinetics-receives-positive-european-regulatory-opinion-for-myqorzo-in-obstructive-hypertrophic-cardiomyopathy 2025-12-12T17:29:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytokinetics-receives-positive-european-regulatory-opinion-for-myqorzo-in-obstructive-hypertrophic-cardiomyopathy 2025-12-12T17:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/csir-and-promptbio-partner-to-advance-ai-driven-precision-medicine-for-african-populations 2025-12-12T17:28:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/csir-and-promptbio-partner-to-advance-ai-driven-precision-medicine-for-african-populations 2025-12-12T17:28:28+00:00 hourly 0.9 https://trial.medpath.com/news/emergent-biosolutions-secures-fda-approval-for-raxibacumab-manufacturing-at-winnipeg-facility 2025-12-12T17:28:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emergent-biosolutions-secures-fda-approval-for-raxibacumab-manufacturing-at-winnipeg-facility 2025-12-12T17:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-new-powder-formulation-of-trofinetide-for-enhanced-rett-syndrome-treatment-flexibility 2025-12-12T17:27:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-new-powder-formulation-of-trofinetide-for-enhanced-rett-syndrome-treatment-flexibility 2025-12-12T17:27:30+00:00 hourly 0.9 https://trial.medpath.com/news/suven-life-sciences-completes-phase-2b-enrollment-for-novel-depression-drug-ropanicant-two-months-ahead-of-schedule 2025-12-12T17:27:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/suven-life-sciences-completes-phase-2b-enrollment-for-novel-depression-drug-ropanicant-two-months-ahead-of-schedule 2025-12-12T17:27:27+00:00 hourly 0.9 https://trial.medpath.com/news/mass-general-brigham-spins-out-aiwithcare-to-revolutionize-clinical-trial-patient-matching-with-ai 2025-12-12T17:26:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mass-general-brigham-spins-out-aiwithcare-to-revolutionize-clinical-trial-patient-matching-with-ai 2025-12-12T17:26:50+00:00 hourly 0.9 https://trial.medpath.com/news/acupuncture-shows-promise-for-treating-cognitive-impairment-in-breast-cancer-survivors 2025-12-12T17:26:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acupuncture-shows-promise-for-treating-cognitive-impairment-in-breast-cancer-survivors 2025-12-12T17:26:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-plans-black-box-warning-for-covid-19-vaccines-amid-safety-concerns 2025-12-12T13:29:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-plans-black-box-warning-for-covid-19-vaccines-amid-safety-concerns 2025-12-12T13:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/uk-and-singapore-launch-first-of-its-kind-regulatory-innovation-corridor-to-accelerate-breakthrough-health-technologies 2025-12-12T13:29:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-and-singapore-launch-first-of-its-kind-regulatory-innovation-corridor-to-accelerate-breakthrough-health-technologies 2025-12-12T13:29:13+00:00 hourly 0.9 https://trial.medpath.com/news/zepbound-weight-loss-drug-enters-clinical-testing-for-long-covid-treatment 2025-12-12T13:28:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zepbound-weight-loss-drug-enters-clinical-testing-for-long-covid-treatment 2025-12-12T13:28:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-plans-black-box-warning-for-covid-19-vaccines-amid-scientific-controversy 2025-12-12T13:28:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-plans-black-box-warning-for-covid-19-vaccines-amid-scientific-controversy 2025-12-12T13:28:05+00:00 hourly 0.9 https://trial.medpath.com/news/elicio-therapeutics-eli-002-7p-demonstrates-antigen-spreading-in-87-of-phase-2-patients 2025-12-12T13:27:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elicio-therapeutics-eli-002-7p-demonstrates-antigen-spreading-in-87-of-phase-2-patients 2025-12-12T13:27:24+00:00 hourly 0.9 https://trial.medpath.com/news/taysha-gene-therapies-advances-tsha-102-to-phase-3-development-for-rett-syndrome-treatment 2025-12-12T13:27:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taysha-gene-therapies-advances-tsha-102-to-phase-3-development-for-rett-syndrome-treatment 2025-12-12T13:27:22+00:00 hourly 0.9 https://trial.medpath.com/news/medline-completes-6-26-billion-ipo-becomes-largest-healthcare-public-offering-of-2025 2025-12-12T13:27:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medline-completes-6-26-billion-ipo-becomes-largest-healthcare-public-offering-of-2025 2025-12-12T13:27:16+00:00 hourly 0.9 https://trial.medpath.com/news/stada-and-bio-thera-s-golimumab-biosimilar-gotenfia-receives-positive-chmp-opinion-for-multiple-autoimmune-conditions 2025-12-12T13:27:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stada-and-bio-thera-s-golimumab-biosimilar-gotenfia-receives-positive-chmp-opinion-for-multiple-autoimmune-conditions 2025-12-12T13:27:11+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-s-autoimmune-biosimilar-avtozma-gains-preferred-status-with-major-u-s-pharmacy-benefit-manager 2025-12-12T13:27:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-s-autoimmune-biosimilar-avtozma-gains-preferred-status-with-major-u-s-pharmacy-benefit-manager 2025-12-12T13:27:08+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharmaceutical-companies-push-fda-to-decouple-facility-inspections-from-drug-approval-timeline 2025-12-12T13:27:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pharmaceutical-companies-push-fda-to-decouple-facility-inspections-from-drug-approval-timeline 2025-12-12T13:27:05+00:00 hourly 0.9 https://trial.medpath.com/news/orphalan-acquires-orphelia-pharma-to-strengthen-rare-disease-portfolio-in-pediatric-neurology-and-oncology 2025-12-12T13:26:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orphalan-acquires-orphelia-pharma-to-strengthen-rare-disease-portfolio-in-pediatric-neurology-and-oncology 2025-12-12T13:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/nyu-abu-dhabi-develops-spheromatrix-platform-to-accelerate-cancer-drug-testing-with-freezable-3d-tumor-models 2025-12-12T13:26:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyu-abu-dhabi-develops-spheromatrix-platform-to-accelerate-cancer-drug-testing-with-freezable-3d-tumor-models 2025-12-12T13:26:51+00:00 hourly 0.9 https://trial.medpath.com/news/ptc-therapeutics-secures-global-approvals-for-sephience-in-pku-treatment-across-canada-and-japan 2025-12-12T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ptc-therapeutics-secures-global-approvals-for-sephience-in-pku-treatment-across-canada-and-japan 2025-12-12T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-reports-strong-q3-2025-performance-with-mnexspike-capturing-24-of-us-covid-vaccine-market 2025-12-12T09:29:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-reports-strong-q3-2025-performance-with-mnexspike-capturing-24-of-us-covid-vaccine-market 2025-12-12T09:29:18+00:00 hourly 0.9 https://trial.medpath.com/news/south-australia-to-launch-car-t-cell-therapy-service-at-royal-adelaide-hospital-by-mid-2026 2025-12-12T09:28:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-australia-to-launch-car-t-cell-therapy-service-at-royal-adelaide-hospital-by-mid-2026 2025-12-12T09:28:19+00:00 hourly 0.9 https://trial.medpath.com/news/first-commercial-gene-therapy-for-hemophilia-a-administered-in-michigan-outside-clinical-trials 2025-12-12T09:27:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-commercial-gene-therapy-for-hemophilia-a-administered-in-michigan-outside-clinical-trials 2025-12-12T09:27:36+00:00 hourly 0.9 https://trial.medpath.com/news/revolution-medicines-receives-fda-breakthrough-therapy-designation-for-daraxonrasib-in-kras-g12-mutant-pancreatic-cancer 2025-12-12T09:27:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolution-medicines-receives-fda-breakthrough-therapy-designation-for-daraxonrasib-in-kras-g12-mutant-pancreatic-cancer 2025-12-12T09:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/republican-led-states-challenge-fda-approval-of-generic-mifepristone-in-federal-lawsuits 2025-12-12T09:26:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/republican-led-states-challenge-fda-approval-of-generic-mifepristone-in-federal-lawsuits 2025-12-12T09:26:58+00:00 hourly 0.9 https://trial.medpath.com/news/xofluza-demonstrates-superior-efficacy-over-tamiflu-in-reducing-hospitalizations-and-emergency-department-visits 2025-12-12T09:25:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xofluza-demonstrates-superior-efficacy-over-tamiflu-in-reducing-hospitalizations-and-emergency-department-visits 2025-12-12T09:25:45+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-explores-acquisition-of-french-biotech-abivax-for-ulcerative-colitis-drug 2025-12-12T05:32:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-explores-acquisition-of-french-biotech-abivax-for-ulcerative-colitis-drug 2025-12-12T05:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/proton-therapy-demonstrates-10-survival-advantage-over-traditional-radiation-in-landmark-head-and-neck-cancer-trial 2025-12-12T05:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proton-therapy-demonstrates-10-survival-advantage-over-traditional-radiation-in-landmark-head-and-neck-cancer-trial 2025-12-12T05:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/aprogen-s-herceptin-biosimilar-ap-063-advances-to-regulatory-approval-without-phase-3-trials 2025-12-12T05:26:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aprogen-s-herceptin-biosimilar-ap-063-advances-to-regulatory-approval-without-phase-3-trials 2025-12-12T05:26:04+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-study-shows-covid-19-vaccines-reduce-emergency-visits-in-children-by-up-to-76-amid-fda-safety-investigation 2025-12-12T01:34:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-study-shows-covid-19-vaccines-reduce-emergency-visits-in-children-by-up-to-76-amid-fda-safety-investigation 2025-12-12T01:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/tenaya-therapeutics-reports-promising-early-results-for-tn-401-gene-therapy-in-rare-heart-disease 2025-12-12T01:31:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenaya-therapeutics-reports-promising-early-results-for-tn-401-gene-therapy-in-rare-heart-disease 2025-12-12T01:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/cycle-pharmaceuticals-acquires-applied-therapeutics-in-0-088-per-share-deal-to-advance-rare-disease-pipeline 2025-12-12T01:30:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cycle-pharmaceuticals-acquires-applied-therapeutics-in-0-088-per-share-deal-to-advance-rare-disease-pipeline 2025-12-12T01:30:37+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-s-opdivo-plus-yervoy-receives-positive-reimbursement-recommendation-for-msi-h-dmmr-colorectal-cancer-in-canada 2025-12-12T01:30:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-s-opdivo-plus-yervoy-receives-positive-reimbursement-recommendation-for-msi-h-dmmr-colorectal-cancer-in-canada 2025-12-12T01:30:01+00:00 hourly 0.9 https://trial.medpath.com/news/anixa-s-alpha-lactalbumin-breast-cancer-vaccine-shows-74-immune-response-rate-in-phase-1-trial 2025-12-12T01:29:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anixa-s-alpha-lactalbumin-breast-cancer-vaccine-shows-74-immune-response-rate-in-phase-1-trial 2025-12-12T01:29:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-lifts-clinical-hold-on-tenaya-s-tn-201-gene-therapy-for-genetic-heart-disease 2025-12-12T01:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-lifts-clinical-hold-on-tenaya-s-tn-201-gene-therapy-for-genetic-heart-disease 2025-12-12T01:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/belzutifan-shows-sustained-efficacy-in-heavily-pretreated-clear-cell-renal-cell-carcinoma-patients 2025-12-12T01:28:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belzutifan-shows-sustained-efficacy-in-heavily-pretreated-clear-cell-renal-cell-carcinoma-patients 2025-12-12T01:28:38+00:00 hourly 0.9 https://trial.medpath.com/news/crinetics-initiates-phase-3-trial-of-atumelnant-for-congenital-adrenal-hyperplasia 2025-12-12T01:28:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crinetics-initiates-phase-3-trial-of-atumelnant-for-congenital-adrenal-hyperplasia 2025-12-12T01:28:30+00:00 hourly 0.9 https://trial.medpath.com/news/evommune-advances-two-novel-inflammatory-disease-programs-following-172-5m-ipo 2025-12-12T01:28:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evommune-advances-two-novel-inflammatory-disease-programs-following-172-5m-ipo 2025-12-12T01:28:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-uplizna-as-first-cd19-targeted-b-cell-therapy-for-generalized-myasthenia-gravis 2025-12-12T01:27:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-uplizna-as-first-cd19-targeted-b-cell-therapy-for-generalized-myasthenia-gravis 2025-12-12T01:27:19+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-juliet-trial-data-shows-car-t-therapy-delivers-durable-survival-in-relapsed-b-cell-lymphoma 2025-12-12T01:26:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-juliet-trial-data-shows-car-t-therapy-delivers-durable-survival-in-relapsed-b-cell-lymphoma 2025-12-12T01:26:04+00:00 hourly 0.9 https://trial.medpath.com/news/cleveland-clinic-s-triple-negative-breast-cancer-vaccine-shows-74-immune-response-rate-in-phase-1-trial 2025-12-12T01:25:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleveland-clinic-s-triple-negative-breast-cancer-vaccine-shows-74-immune-response-rate-in-phase-1-trial 2025-12-12T01:25:48+00:00 hourly 0.9 https://trial.medpath.com/news/geron-projects-strong-2026-revenue-growth-for-rytelo-following-strategic-restructuring 2025-12-11T21:40:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geron-projects-strong-2026-revenue-growth-for-rytelo-following-strategic-restructuring 2025-12-11T21:40:05+00:00 hourly 0.9 https://trial.medpath.com/news/basilea-and-phare-bio-partner-to-develop-ai-designed-broad-spectrum-antibiotic 2025-12-11T21:38:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/basilea-and-phare-bio-partner-to-develop-ai-designed-broad-spectrum-antibiotic 2025-12-11T21:38:45+00:00 hourly 0.9 https://trial.medpath.com/news/beyondspring-s-plinabulin-shows-consistent-survival-benefit-in-egfr-wild-type-nsclc-after-anti-pd-l-1-failure 2025-12-11T21:38:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyondspring-s-plinabulin-shows-consistent-survival-benefit-in-egfr-wild-type-nsclc-after-anti-pd-l-1-failure 2025-12-11T21:38:21+00:00 hourly 0.9 https://trial.medpath.com/news/rezolute-s-ersodetug-fails-phase-3-trial-for-congenital-hyperinsulinism-stock-plunges-88 2025-12-11T21:37:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rezolute-s-ersodetug-fails-phase-3-trial-for-congenital-hyperinsulinism-stock-plunges-88 2025-12-11T21:37:56+00:00 hourly 0.9 https://trial.medpath.com/news/accenture-invests-in-ryght-ai-to-accelerate-clinical-trial-execution-through-agentic-ai-platform 2025-12-11T21:37:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accenture-invests-in-ryght-ai-to-accelerate-clinical-trial-execution-through-agentic-ai-platform 2025-12-11T21:37:15+00:00 hourly 0.9 https://trial.medpath.com/news/innocare-s-next-generation-trk-inhibitor-zurletrectinib-receives-nmpa-approval-in-china-for-ntrk-fusion-positive-solid-tumors 2025-12-11T21:37:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innocare-s-next-generation-trk-inhibitor-zurletrectinib-receives-nmpa-approval-in-china-for-ntrk-fusion-positive-solid-tumors 2025-12-11T21:37:01+00:00 hourly 0.9 https://trial.medpath.com/news/immunewalk-therapeutics-reports-positive-phase-1-results-for-iw-601-novel-myeloid-cell-inhibitor-for-inflammatory-diseases 2025-12-11T21:36:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunewalk-therapeutics-reports-positive-phase-1-results-for-iw-601-novel-myeloid-cell-inhibitor-for-inflammatory-diseases 2025-12-11T21:36:14+00:00 hourly 0.9 https://trial.medpath.com/news/valinor-secures-13-million-seed-funding-to-advance-ai-driven-patient-selection-platform-for-clinical-trials 2025-12-11T21:36:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valinor-secures-13-million-seed-funding-to-advance-ai-driven-patient-selection-platform-for-clinical-trials 2025-12-11T21:36:11+00:00 hourly 0.9 https://trial.medpath.com/news/less-invasive-axillary-staging-procedures-show-noninferiority-to-standard-lymph-node-dissection-in-breast-cancer 2025-12-11T21:35:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/less-invasive-axillary-staging-procedures-show-noninferiority-to-standard-lymph-node-dissection-in-breast-cancer 2025-12-11T21:35:08+00:00 hourly 0.9 https://trial.medpath.com/news/intensity-therapeutics-reports-improved-safety-profile-for-int230-6-in-triple-negative-breast-cancer-trial 2025-12-11T21:35:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intensity-therapeutics-reports-improved-safety-profile-for-int230-6-in-triple-negative-breast-cancer-trial 2025-12-11T21:35:05+00:00 hourly 0.9 https://trial.medpath.com/news/roswell-park-researchers-develop-il-36-gamma-armored-car-t-cells-to-eradicate-solid-tumors 2025-12-11T21:35:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roswell-park-researchers-develop-il-36-gamma-armored-car-t-cells-to-eradicate-solid-tumors 2025-12-11T21:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/two-novel-therapies-show-promise-for-neovascular-amd-duravyu-insert-and-ixo-vec-gene-therapy-demonstrate-safety-and-efficacy-in-phase-2-trials 2025-12-11T21:34:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-novel-therapies-show-promise-for-neovascular-amd-duravyu-insert-and-ixo-vec-gene-therapy-demonstrate-safety-and-efficacy-in-phase-2-trials 2025-12-11T21:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/preoperative-radiation-enhances-immune-response-in-hr-positive-breast-cancer-when-combined-with-pembrolizumab 2025-12-11T21:34:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/preoperative-radiation-enhances-immune-response-in-hr-positive-breast-cancer-when-combined-with-pembrolizumab 2025-12-11T21:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/corbus-and-eli-lilly-report-positive-obesity-drug-trial-results-driving-stock-gains 2025-12-11T21:32:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corbus-and-eli-lilly-report-positive-obesity-drug-trial-results-driving-stock-gains 2025-12-11T21:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-announces-771-million-manufacturing-expansion-in-north-carolina-creating-700-jobs 2025-12-11T21:32:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-announces-771-million-manufacturing-expansion-in-north-carolina-creating-700-jobs 2025-12-11T21:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-cagrisema-falls-short-against-eli-lilly-s-tirzepatide-in-obesity-trial 2025-12-11T21:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-cagrisema-falls-short-against-eli-lilly-s-tirzepatide-in-obesity-trial 2025-12-11T21:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/roivant-accelerates-pipeline-timelines-with-multiple-late-stage-programs-advancing-toward-market 2025-12-11T21:31:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roivant-accelerates-pipeline-timelines-with-multiple-late-stage-programs-advancing-toward-market 2025-12-11T21:31:07+00:00 hourly 0.9 https://trial.medpath.com/news/everest-medicines-secures-exclusive-greater-china-rights-to-novel-pcsk9-inhibitor-lerodalcibep 2025-12-11T21:29:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/everest-medicines-secures-exclusive-greater-china-rights-to-novel-pcsk9-inhibitor-lerodalcibep 2025-12-11T21:29:38+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-computing-breakthroughs-promise-to-transform-drug-discovery-by-2028 2025-12-11T21:28:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quantum-computing-breakthroughs-promise-to-transform-drug-discovery-by-2028 2025-12-11T21:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/ivosidenib-combination-demonstrates-real-world-efficacy-in-idh1-mutated-aml-matching-clinical-trial-results 2025-12-11T21:28:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ivosidenib-combination-demonstrates-real-world-efficacy-in-idh1-mutated-aml-matching-clinical-trial-results 2025-12-11T21:28:47+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-trial-finds-no-oncologic-benefit-from-routine-preoperative-mri-in-early-stage-breast-cancer 2025-12-11T21:27:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-trial-finds-no-oncologic-benefit-from-routine-preoperative-mri-in-early-stage-breast-cancer 2025-12-11T21:27:42+00:00 hourly 0.9 https://trial.medpath.com/news/baseline-therapeutics-launches-with-novel-glp-1-approach-for-substance-use-disorders 2025-12-11T21:26:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/baseline-therapeutics-launches-with-novel-glp-1-approach-for-substance-use-disorders 2025-12-11T21:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/tivic-health-acquires-manufacturing-assets-to-accelerate-entolimod-development-with-90m-financing-package 2025-12-11T17:44:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tivic-health-acquires-manufacturing-assets-to-accelerate-entolimod-development-with-90m-financing-package 2025-12-11T17:44:31+00:00 hourly 0.9 https://trial.medpath.com/news/avenzo-s-cdk2-inhibitor-avzo-021-shows-promising-activity-in-breast-and-ovarian-cancer-patients 2025-12-11T17:43:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avenzo-s-cdk2-inhibitor-avzo-021-shows-promising-activity-in-breast-and-ovarian-cancer-patients 2025-12-11T17:43:29+00:00 hourly 0.9 https://trial.medpath.com/news/renovorx-presents-promising-pharmacokinetic-data-for-tamp-therapy-platform-at-asco-gi-2026 2025-12-11T17:42:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renovorx-presents-promising-pharmacokinetic-data-for-tamp-therapy-platform-at-asco-gi-2026 2025-12-11T17:42:50+00:00 hourly 0.9 https://trial.medpath.com/news/purple-biotech-s-captn-3-platform-shows-promise-against-treatment-resistant-cancers-with-dual-tri-specific-antibodies 2025-12-11T17:41:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/purple-biotech-s-captn-3-platform-shows-promise-against-treatment-resistant-cancers-with-dual-tri-specific-antibodies 2025-12-11T17:41:25+00:00 hourly 0.9 https://trial.medpath.com/news/tuhura-biosciences-advances-multi-platform-cancer-immunotherapy-pipeline-with-15-6m-financing 2025-12-11T17:38:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tuhura-biosciences-advances-multi-platform-cancer-immunotherapy-pipeline-with-15-6m-financing 2025-12-11T17:38:33+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-nmpa-accepts-nda-for-novel-brain-cytoprotectant-y-3-for-acute-ischemic-stroke-treatment 2025-12-11T17:37:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-nmpa-accepts-nda-for-novel-brain-cytoprotectant-y-3-for-acute-ischemic-stroke-treatment 2025-12-11T17:37:38+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharmaceuticals-secures-fda-approval-for-generic-zylet-ophthalmic-suspension-with-cgt-exclusivity 2025-12-11T17:37:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alembic-pharmaceuticals-secures-fda-approval-for-generic-zylet-ophthalmic-suspension-with-cgt-exclusivity 2025-12-11T17:37:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-proposes-first-new-sunscreen-active-ingredient-approval-in-25-years-with-bemotrizinol 2025-12-11T17:37:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-proposes-first-new-sunscreen-active-ingredient-approval-in-25-years-with-bemotrizinol 2025-12-11T17:37:26+00:00 hourly 0.9 https://trial.medpath.com/news/prolynx-raises-70-million-to-develop-extended-release-obesity-drugs-with-monthly-and-quarterly-dosing 2025-12-11T17:37:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prolynx-raises-70-million-to-develop-extended-release-obesity-drugs-with-monthly-and-quarterly-dosing 2025-12-11T17:37:24+00:00 hourly 0.9 https://trial.medpath.com/news/proteonic-s-2g-unic-technology-licensed-by-ginkgo-bioworks-for-22-2m-barda-funded-anti-filovirus-antibody-manufacturing-project 2025-12-11T17:37:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proteonic-s-2g-unic-technology-licensed-by-ginkgo-bioworks-for-22-2m-barda-funded-anti-filovirus-antibody-manufacturing-project 2025-12-11T17:37:12+00:00 hourly 0.9 https://trial.medpath.com/news/china-advances-ai-driven-drug-development-with-first-phase-3-trial-and-new-platform-launch 2025-12-11T17:37:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-advances-ai-driven-drug-development-with-first-phase-3-trial-and-new-platform-launch 2025-12-11T17:37:09+00:00 hourly 0.9 https://trial.medpath.com/news/rezolute-s-phase-3-trial-for-congenital-hyperinsulinism-drug-fails-to-meet-primary-endpoints 2025-12-11T17:37:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rezolute-s-phase-3-trial-for-congenital-hyperinsulinism-drug-fails-to-meet-primary-endpoints 2025-12-11T17:37:04+00:00 hourly 0.9 https://trial.medpath.com/news/autobahn-labs-and-astellas-form-strategic-partnership-to-accelerate-academic-drug-discovery 2025-12-11T17:37:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/autobahn-labs-and-astellas-form-strategic-partnership-to-accelerate-academic-drug-discovery 2025-12-11T17:37:01+00:00 hourly 0.9 https://trial.medpath.com/news/eu-reaches-landmark-deal-on-pharmaceutical-legislation-reform-after-three-years-of-negotiations 2025-12-11T17:36:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-reaches-landmark-deal-on-pharmaceutical-legislation-reform-after-three-years-of-negotiations 2025-12-11T17:36:59+00:00 hourly 0.9 https://trial.medpath.com/news/medra-secures-52-million-series-a-to-develop-ai-powered-autonomous-drug-discovery-platform 2025-12-11T17:36:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medra-secures-52-million-series-a-to-develop-ai-powered-autonomous-drug-discovery-platform 2025-12-11T17:36:56+00:00 hourly 0.9 https://trial.medpath.com/news/inotiv-partners-with-vugene-to-advance-ai-driven-drug-discovery-through-multi-omics-platform-integration 2025-12-11T17:36:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inotiv-partners-with-vugene-to-advance-ai-driven-drug-discovery-through-multi-omics-platform-integration 2025-12-11T17:36:53+00:00 hourly 0.9 https://trial.medpath.com/news/ophirex-advances-varespladib-for-snakebite-treatment-under-fda-animal-rule-pathway 2025-12-11T17:36:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ophirex-advances-varespladib-for-snakebite-treatment-under-fda-animal-rule-pathway 2025-12-11T17:36:28+00:00 hourly 0.9 https://trial.medpath.com/news/cadrenal-therapeutics-acquires-first-in-class-12-lox-inhibitor-vlx-1005-for-heparin-induced-thrombocytopenia-treatment 2025-12-11T17:35:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cadrenal-therapeutics-acquires-first-in-class-12-lox-inhibitor-vlx-1005-for-heparin-induced-thrombocytopenia-treatment 2025-12-11T17:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/ataibeckley-secures-key-u-s-patent-for-emp-01-psychedelic-therapy-extending-exclusivity-through-2043 2025-12-11T17:34:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ataibeckley-secures-key-u-s-patent-for-emp-01-psychedelic-therapy-extending-exclusivity-through-2043 2025-12-11T17:34:47+00:00 hourly 0.9 https://trial.medpath.com/news/enliven-therapeutics-appoints-rick-fair-as-ceo-to-lead-elvn-001-through-phase-3-trial 2025-12-11T17:33:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enliven-therapeutics-appoints-rick-fair-as-ceo-to-lead-elvn-001-through-phase-3-trial 2025-12-11T17:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/viromissile-initiates-first-in-human-trial-of-idov-immune-oncolytic-virus-therapy-for-advanced-solid-tumors 2025-12-11T17:33:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viromissile-initiates-first-in-human-trial-of-idov-immune-oncolytic-virus-therapy-for-advanced-solid-tumors 2025-12-11T17:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/corbus-pharmaceuticals-crb-913-shows-promising-weight-loss-results-in-phase-1a-obesity-trial 2025-12-11T17:33:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corbus-pharmaceuticals-crb-913-shows-promising-weight-loss-results-in-phase-1a-obesity-trial 2025-12-11T17:33:45+00:00 hourly 0.9 https://trial.medpath.com/news/quanterix-and-emocog-partner-to-bring-ultra-sensitive-alzheimer-s-blood-testing-to-korea 2025-12-11T17:33:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quanterix-and-emocog-partner-to-bring-ultra-sensitive-alzheimer-s-blood-testing-to-korea 2025-12-11T17:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/trogenix-secures-95m-series-a-to-advance-trojan-horse-gene-therapy-for-glioblastoma 2025-12-11T17:32:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trogenix-secures-95m-series-a-to-advance-trojan-horse-gene-therapy-for-glioblastoma 2025-12-11T17:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/gerosynth-labs-secures-fda-veterinary-approval-for-multi-species-oncology-drug-trials 2025-12-11T17:32:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gerosynth-labs-secures-fda-veterinary-approval-for-multi-species-oncology-drug-trials 2025-12-11T17:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/nanology-advances-novel-intratumoral-cisplatin-formulation-for-fatal-pediatric-brain-cancer-dipg 2025-12-11T17:32:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanology-advances-novel-intratumoral-cisplatin-formulation-for-fatal-pediatric-brain-cancer-dipg 2025-12-11T17:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/sen-jam-pharmaceutical-secures-equity-backed-partnership-for-phase-3-trial-of-first-in-category-hangover-prevention-therapy 2025-12-11T17:32:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sen-jam-pharmaceutical-secures-equity-backed-partnership-for-phase-3-trial-of-first-in-category-hangover-prevention-therapy 2025-12-11T17:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/her2-negative-breast-cancer-pipeline-expands-with-75-therapies-from-70-companies 2025-12-11T17:32:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/her2-negative-breast-cancer-pipeline-expands-with-75-therapies-from-70-companies 2025-12-11T17:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/baxter-smart-infusion-pump-emr-integration-reduces-safety-alerts-by-up-to-50-in-real-world-study 2025-12-11T17:32:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/baxter-smart-infusion-pump-emr-integration-reduces-safety-alerts-by-up-to-50-in-real-world-study 2025-12-11T17:32:28+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-s-bhv-1510-shows-promising-efficacy-in-phase-1-trial-combining-trop2-adc-with-cemiplimab 2025-12-11T17:32:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biohaven-s-bhv-1510-shows-promising-efficacy-in-phase-1-trial-combining-trop2-adc-with-cemiplimab 2025-12-11T17:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/tempramed-launches-vivi-cap-smart-first-digital-temperature-protection-device-for-insulin-and-glp-1-medications 2025-12-11T17:32:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempramed-launches-vivi-cap-smart-first-digital-temperature-protection-device-for-insulin-and-glp-1-medications 2025-12-11T17:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharma-giants-return-to-neuroscience-with-26-6-billion-in-strategic-acquisitions 2025-12-11T17:31:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pharma-giants-return-to-neuroscience-with-26-6-billion-in-strategic-acquisitions 2025-12-11T17:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/galderma-initiates-phase-ii-trial-of-nemolizumab-for-chronic-pruritus-of-unknown-origin 2025-12-11T17:29:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galderma-initiates-phase-ii-trial-of-nemolizumab-for-chronic-pruritus-of-unknown-origin 2025-12-11T17:29:46+00:00 hourly 0.9 https://trial.medpath.com/news/disco-pharmaceuticals-secures-eur36m-seed-financing-and-appoints-new-ceo-to-advance-surfaceome-targeted-cancer-therapies 2025-12-11T17:29:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/disco-pharmaceuticals-secures-eur36m-seed-financing-and-appoints-new-ceo-to-advance-surfaceome-targeted-cancer-therapies 2025-12-11T17:29:43+00:00 hourly 0.9 https://trial.medpath.com/news/ac-immune-s-alpha-synuclein-immunotherapy-shows-promise-in-slowing-parkinson-s-disease-progression 2025-12-11T17:29:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ac-immune-s-alpha-synuclein-immunotherapy-shows-promise-in-slowing-parkinson-s-disease-progression 2025-12-11T17:29:22+00:00 hourly 0.9 https://trial.medpath.com/news/guardant-health-partners-with-trial-library-to-expand-cancer-clinical-trial-access-using-ai-and-genomic-data 2025-12-11T17:28:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guardant-health-partners-with-trial-library-to-expand-cancer-clinical-trial-access-using-ai-and-genomic-data 2025-12-11T17:28:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-at-home-brain-stimulation-device-for-major-depression-treatment 2025-12-11T17:28:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-at-home-brain-stimulation-device-for-major-depression-treatment 2025-12-11T17:28:01+00:00 hourly 0.9 https://trial.medpath.com/news/uk-achieves-global-first-patient-recruitment-in-novel-copd-treatment-trial 2025-12-11T17:27:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-achieves-global-first-patient-recruitment-in-novel-copd-treatment-trial 2025-12-11T17:27:53+00:00 hourly 0.9 https://trial.medpath.com/news/60-degrees-pharmaceuticals-expands-arakoda-sales-strategy-following-positive-commercial-pilot-results 2025-12-11T17:27:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/60-degrees-pharmaceuticals-expands-arakoda-sales-strategy-following-positive-commercial-pilot-results 2025-12-11T17:27:30+00:00 hourly 0.9 https://trial.medpath.com/news/transcode-therapeutics-advances-ttx-mc138-to-phase-2a-trial-for-minimal-residual-disease-in-colorectal-cancer 2025-12-11T17:26:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcode-therapeutics-advances-ttx-mc138-to-phase-2a-trial-for-minimal-residual-disease-in-colorectal-cancer 2025-12-11T17:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/atossa-therapeutics-receives-fda-rare-pediatric-disease-designation-for-z-endoxifen-in-duchenne-muscular-dystrophy 2025-12-11T17:26:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atossa-therapeutics-receives-fda-rare-pediatric-disease-designation-for-z-endoxifen-in-duchenne-muscular-dystrophy 2025-12-11T17:26:02+00:00 hourly 0.9 https://trial.medpath.com/news/modified-water-vapor-therapy-shows-promise-for-large-volume-benign-prostatic-hyperplasia-treatment 2025-12-11T16:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modified-water-vapor-therapy-shows-promise-for-large-volume-benign-prostatic-hyperplasia-treatment 2025-12-11T16:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/medicines-for-malaria-venture-joins-iicon-consortium-to-accelerate-infectious-disease-drug-discovery 2025-12-11T13:29:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicines-for-malaria-venture-joins-iicon-consortium-to-accelerate-infectious-disease-drug-discovery 2025-12-11T13:29:34+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-scientists-develop-novel-cancer-therapy-using-reprogrammed-mast-cells-to-convert-cold-tumors-into-hot-targets 2025-12-11T13:28:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-scientists-develop-novel-cancer-therapy-using-reprogrammed-mast-cells-to-convert-cold-tumors-into-hot-targets 2025-12-11T13:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/mabylon-initiates-first-in-human-trial-of-novel-tri-specific-antibody-my006-for-peanut-allergy-prevention 2025-12-11T13:27:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabylon-initiates-first-in-human-trial-of-novel-tri-specific-antibody-my006-for-peanut-allergy-prevention 2025-12-11T13:27:26+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-biosciences-completes-enrollment-in-pivotal-trial-for-darovasertib-combination-in-metastatic-uveal-melanoma 2025-12-11T13:25:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ideaya-biosciences-completes-enrollment-in-pivotal-trial-for-darovasertib-combination-in-metastatic-uveal-melanoma 2025-12-11T13:25:30+00:00 hourly 0.9 https://trial.medpath.com/news/bioversys-initiates-phase-3-trial-for-bv100-antibiotic-following-50-mortality-reduction-in-phase-2 2025-12-11T13:25:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioversys-initiates-phase-3-trial-for-bv100-antibiotic-following-50-mortality-reduction-in-phase-2 2025-12-11T13:25:27+00:00 hourly 0.9 https://trial.medpath.com/news/centessa-pharmaceuticals-advances-orexin-agonist-pipeline-with-leadership-transition-and-promising-clinical-data 2025-12-11T12:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/centessa-pharmaceuticals-advances-orexin-agonist-pipeline-with-leadership-transition-and-promising-clinical-data 2025-12-11T12:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/rhythm-pharmaceuticals-reports-positive-phase-2-results-for-setmelanotide-in-prader-willi-syndrome 2025-12-11T09:27:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rhythm-pharmaceuticals-reports-positive-phase-2-results-for-setmelanotide-in-prader-willi-syndrome 2025-12-11T09:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/zealand-pharma-unveils-metabolic-frontier-2030-strategy-with-otr-therapeutics-partnership 2025-12-11T09:26:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zealand-pharma-unveils-metabolic-frontier-2030-strategy-with-otr-therapeutics-partnership 2025-12-11T09:26:44+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-secures-chinese-approval-for-two-rare-blood-disorder-therapies-qfitlia-and-cablivi 2025-12-11T09:26:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-secures-chinese-approval-for-two-rare-blood-disorder-therapies-qfitlia-and-cablivi 2025-12-11T09:26:35+00:00 hourly 0.9 https://trial.medpath.com/news/deep-intelligent-pharma-secures-50m-series-d-to-expand-ai-powered-clinical-documentation-platform 2025-12-11T09:26:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deep-intelligent-pharma-secures-50m-series-d-to-expand-ai-powered-clinical-documentation-platform 2025-12-11T09:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/cell-and-gene-therapy-market-projected-to-reach-105-billion-by-2033-as-clinical-pipeline-expands 2025-12-11T09:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cell-and-gene-therapy-market-projected-to-reach-105-billion-by-2033-as-clinical-pipeline-expands 2025-12-11T09:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-pharmaceutical-establishes-u-s-partnering-office-to-accelerate-global-open-innovation-strategy 2025-12-11T09:25:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-pharmaceutical-establishes-u-s-partnering-office-to-accelerate-global-open-innovation-strategy 2025-12-11T09:25:28+00:00 hourly 0.9 https://trial.medpath.com/news/pll-therapeutics-advances-gut-targeting-als-therapy-to-phase-ii-after-positive-safety-results 2025-12-11T05:29:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pll-therapeutics-advances-gut-targeting-als-therapy-to-phase-ii-after-positive-safety-results 2025-12-11T05:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/heartbeam-receives-fda-clearance-for-first-cable-free-12-lead-ecg-device-for-home-arrhythmia-assessment 2025-12-11T05:27:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heartbeam-receives-fda-clearance-for-first-cable-free-12-lead-ecg-device-for-home-arrhythmia-assessment 2025-12-11T05:27:21+00:00 hourly 0.9 https://trial.medpath.com/news/blood-tests-show-promise-for-personalized-breast-cancer-treatment-selection 2025-12-11T05:26:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-tests-show-promise-for-personalized-breast-cancer-treatment-selection 2025-12-11T05:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/senator-hawley-challenges-fda-over-alleged-delay-in-mifepristone-safety-review 2025-12-11T05:26:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senator-hawley-challenges-fda-over-alleged-delay-in-mifepristone-safety-review 2025-12-11T05:26:14+00:00 hourly 0.9 https://trial.medpath.com/news/natera-s-signatera-mrd-test-shows-powerful-prognostic-value-in-phase-iii-pallas-breast-cancer-study 2025-12-11T05:25:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natera-s-signatera-mrd-test-shows-powerful-prognostic-value-in-phase-iii-pallas-breast-cancer-study 2025-12-11T05:25:28+00:00 hourly 0.9 https://trial.medpath.com/news/ro-telehealth-platform-demonstrates-clinical-trial-level-semaglutide-outcomes-in-real-world-study 2025-12-11T05:25:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ro-telehealth-platform-demonstrates-clinical-trial-level-semaglutide-outcomes-in-real-world-study 2025-12-11T05:25:22+00:00 hourly 0.9 https://trial.medpath.com/news/bbot-presents-first-in-class-ras-pi3ka-breaker-bbo-10203-data-at-sabcs-launches-phase-1-trial 2025-12-11T01:33:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bbot-presents-first-in-class-ras-pi3ka-breaker-bbo-10203-data-at-sabcs-launches-phase-1-trial 2025-12-11T01:33:40+00:00 hourly 0.9 https://trial.medpath.com/news/gri-bio-s-gri-0621-shows-promise-in-phase-2a-ipf-trial-with-disease-modifying-potential 2025-12-11T01:30:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gri-bio-s-gri-0621-shows-promise-in-phase-2a-ipf-trial-with-disease-modifying-potential 2025-12-11T01:30:14+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-partners-with-nanexa-on-pharmashell-drug-delivery-technology-in-500m-deal 2025-12-11T01:29:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-partners-with-nanexa-on-pharmashell-drug-delivery-technology-in-500m-deal 2025-12-11T01:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/aardvark-therapeutics-initiates-international-expansion-of-phase-3-hero-trial-for-prader-willi-syndrome-treatment 2025-12-11T01:28:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aardvark-therapeutics-initiates-international-expansion-of-phase-3-hero-trial-for-prader-willi-syndrome-treatment 2025-12-11T01:28:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expert-panel-calls-for-testosterone-therapy-label-revisions-following-cardiovascular-safety-data 2025-12-11T01:28:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expert-panel-calls-for-testosterone-therapy-label-revisions-following-cardiovascular-safety-data 2025-12-11T01:28:22+00:00 hourly 0.9 https://trial.medpath.com/news/lir-life-sciences-advances-needle-free-obesity-treatment-with-novel-transdermal-glp-gip-delivery-platform 2025-12-11T01:28:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lir-life-sciences-advances-needle-free-obesity-treatment-with-novel-transdermal-glp-gip-delivery-platform 2025-12-11T01:28:19+00:00 hourly 0.9 https://trial.medpath.com/news/serina-therapeutics-responds-to-fda-clinical-hold-on-ser-252-parkinson-s-disease-treatment 2025-12-11T01:28:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/serina-therapeutics-responds-to-fda-clinical-hold-on-ser-252-parkinson-s-disease-treatment 2025-12-11T01:28:17+00:00 hourly 0.9 https://trial.medpath.com/news/mediwound-s-nexobrid-r-demonstrates-92-5-reduction-in-traumatic-tattoos-from-blast-and-abrasion-injuries 2025-12-11T01:26:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mediwound-s-nexobrid-r-demonstrates-92-5-reduction-in-traumatic-tattoos-from-blast-and-abrasion-injuries 2025-12-11T01:26:36+00:00 hourly 0.9 https://trial.medpath.com/news/karyopharm-prepares-for-pivotal-2026-with-phase-3-myelofibrosis-data-expected-in-march 2025-12-11T01:26:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/karyopharm-prepares-for-pivotal-2026-with-phase-3-myelofibrosis-data-expected-in-march 2025-12-11T01:26:02+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-multimodal-models-show-superior-breast-cancer-recurrence-risk-prediction-in-tailorx-validation-study 2025-12-11T01:25:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-multimodal-models-show-superior-breast-cancer-recurrence-risk-prediction-in-tailorx-validation-study 2025-12-11T01:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/medinatura-issues-nationwide-recall-of-reboost-nasal-spray-due-to-life-threatening-microbial-contamination 2025-12-10T21:40:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medinatura-issues-nationwide-recall-of-reboost-nasal-spray-due-to-life-threatening-microbial-contamination 2025-12-10T21:40:36+00:00 hourly 0.9 https://trial.medpath.com/news/carrick-therapeutics-reports-promising-phase-2-results-for-cdk7-inhibitor-samuraciclib-in-advanced-breast-cancer 2025-12-10T21:39:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carrick-therapeutics-reports-promising-phase-2-results-for-cdk7-inhibitor-samuraciclib-in-advanced-breast-cancer 2025-12-10T21:39:36+00:00 hourly 0.9 https://trial.medpath.com/news/fda-launches-tempo-digital-health-pilot-to-accelerate-access-to-chronic-disease-management-technologies 2025-12-10T21:39:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-launches-tempo-digital-health-pilot-to-accelerate-access-to-chronic-disease-management-technologies 2025-12-10T21:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/fibrobiologics-files-patent-for-novel-fibroblast-based-chondrocyte-spheroid-platform-targeting-orthopedic-conditions 2025-12-10T21:36:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fibrobiologics-files-patent-for-novel-fibroblast-based-chondrocyte-spheroid-platform-targeting-orthopedic-conditions 2025-12-10T21:36:19+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-reports-100-procedural-success-in-atrial-fibrillation-study-and-durable-remissions-in-multiple-myeloma-trial 2025-12-10T21:36:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-reports-100-procedural-success-in-atrial-fibrillation-study-and-durable-remissions-in-multiple-myeloma-trial 2025-12-10T21:36:16+00:00 hourly 0.9 https://trial.medpath.com/news/romosozumab-demonstrates-superior-fracture-reduction-compared-to-pth-analogs-in-real-world-study 2025-12-10T21:35:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/romosozumab-demonstrates-superior-fracture-reduction-compared-to-pth-analogs-in-real-world-study 2025-12-10T21:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/trispecific-antibody-shows-promise-for-immunotherapy-resistant-tumors-through-multi-target-approach 2025-12-10T21:33:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trispecific-antibody-shows-promise-for-immunotherapy-resistant-tumors-through-multi-target-approach 2025-12-10T21:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/indivumed-partners-with-university-of-rochester-to-accelerate-precision-cancer-therapeutic-discovery 2025-12-10T21:33:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indivumed-partners-with-university-of-rochester-to-accelerate-precision-cancer-therapeutic-discovery 2025-12-10T21:33:25+00:00 hourly 0.9 https://trial.medpath.com/news/bioxodes-secures-eur5-5-million-to-advance-first-in-class-stroke-treatment-toward-pivotal-trial 2025-12-10T21:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioxodes-secures-eur5-5-million-to-advance-first-in-class-stroke-treatment-toward-pivotal-trial 2025-12-10T21:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/children-s-health-defense-petitions-fda-to-revoke-covid-19-vaccine-licenses-over-regulatory-compliance-concerns 2025-12-10T21:31:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/children-s-health-defense-petitions-fda-to-revoke-covid-19-vaccine-licenses-over-regulatory-compliance-concerns 2025-12-10T21:31:46+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-identify-fdx2-as-potential-drug-target-for-friedreich-s-ataxia-treatment 2025-12-10T21:31:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-identify-fdx2-as-potential-drug-target-for-friedreich-s-ataxia-treatment 2025-12-10T21:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/maia-biotechnology-advances-first-in-class-telomere-targeting-therapy-ateganosine-into-phase-3-for-treatment-resistant-nsclc 2025-12-10T21:27:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maia-biotechnology-advances-first-in-class-telomere-targeting-therapy-ateganosine-into-phase-3-for-treatment-resistant-nsclc 2025-12-10T21:27:17+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-study-identifies-biological-mechanism-behind-mrna-covid-19-vaccine-associated-myocarditis 2025-12-10T21:26:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-study-identifies-biological-mechanism-behind-mrna-covid-19-vaccine-associated-myocarditis 2025-12-10T21:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/genfit-s-gns561-combination-therapy-shows-disease-stabilization-in-advanced-cholangiocarcinoma-patients 2025-12-10T21:26:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genfit-s-gns561-combination-therapy-shows-disease-stabilization-in-advanced-cholangiocarcinoma-patients 2025-12-10T21:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/sentynl-therapeutics-partners-with-mytomorrows-to-expand-global-access-to-rare-disease-treatments 2025-12-10T21:26:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sentynl-therapeutics-partners-with-mytomorrows-to-expand-global-access-to-rare-disease-treatments 2025-12-10T21:26:32+00:00 hourly 0.9 https://trial.medpath.com/news/van-andel-institute-and-cure-parkinson-s-renew-1-5m-annual-funding-for-world-s-largest-parkinson-s-drug-repurposing-initiative 2025-12-10T21:25:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/van-andel-institute-and-cure-parkinson-s-renew-1-5m-annual-funding-for-world-s-largest-parkinson-s-drug-repurposing-initiative 2025-12-10T21:25:59+00:00 hourly 0.9 https://trial.medpath.com/news/curis-secures-20-2-million-funding-to-advance-emavusertib-cancer-pipeline-following-positive-aml-trial-results 2025-12-10T17:37:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curis-secures-20-2-million-funding-to-advance-emavusertib-cancer-pipeline-following-positive-aml-trial-results 2025-12-10T17:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/staar-surgical-shareholders-reject-alcon-s-1-6-billion-acquisition-offer-deal-terminated 2025-12-10T17:37:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/staar-surgical-shareholders-reject-alcon-s-1-6-billion-acquisition-offer-deal-terminated 2025-12-10T17:37:06+00:00 hourly 0.9 https://trial.medpath.com/news/azura-ophthalmics-receives-positive-fda-feedback-for-first-in-class-dry-eye-treatment-targeting-meibomian-gland-dysfunction 2025-12-10T17:35:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/azura-ophthalmics-receives-positive-fda-feedback-for-first-in-class-dry-eye-treatment-targeting-meibomian-gland-dysfunction 2025-12-10T17:35:42+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-allocates-6-billion-for-strategic-acquisitions-in-internal-medicine-and-immunology-following-metsera-deal 2025-12-10T17:35:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-allocates-6-billion-for-strategic-acquisitions-in-internal-medicine-and-immunology-following-metsera-deal 2025-12-10T17:35:31+00:00 hourly 0.9 https://trial.medpath.com/news/psithera-raises-47-5-million-series-a-to-develop-oral-drugs-for-tnf-superfamily-targets 2025-12-10T17:35:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psithera-raises-47-5-million-series-a-to-develop-oral-drugs-for-tnf-superfamily-targets 2025-12-10T17:35:20+00:00 hourly 0.9 https://trial.medpath.com/news/northwestern-scientists-develop-15-minute-hepatitis-c-test-enabling-same-day-treatment 2025-12-10T17:35:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northwestern-scientists-develop-15-minute-hepatitis-c-test-enabling-same-day-treatment 2025-12-10T17:35:17+00:00 hourly 0.9 https://trial.medpath.com/news/dare-bioscience-launches-first-evidence-based-topical-sildenafil-cream-for-women-s-sexual-health 2025-12-10T17:34:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dare-bioscience-launches-first-evidence-based-topical-sildenafil-cream-for-women-s-sexual-health 2025-12-10T17:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/russia-completes-first-production-batches-of-personalized-mrna-cancer-vaccine 2025-12-10T17:34:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/russia-completes-first-production-batches-of-personalized-mrna-cancer-vaccine 2025-12-10T17:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-five-novel-lung-cancer-therapies-in-2025-advancing-precision-medicine-and-immunotherapy 2025-12-10T17:33:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-five-novel-lung-cancer-therapies-in-2025-advancing-precision-medicine-and-immunotherapy 2025-12-10T17:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/igyxos-biotherapeutics-reports-positive-phase-1-results-for-igx12-first-in-class-monoclonal-antibody-targeting-male-and-female-infertility 2025-12-10T17:32:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/igyxos-biotherapeutics-reports-positive-phase-1-results-for-igx12-first-in-class-monoclonal-antibody-targeting-male-and-female-infertility 2025-12-10T17:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/bantam-pharmaceutical-initiates-first-in-class-btm-3566-phase-1-trial-for-aggressive-cancers 2025-12-10T17:32:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bantam-pharmaceutical-initiates-first-in-class-btm-3566-phase-1-trial-for-aggressive-cancers 2025-12-10T17:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/barinthus-bio-s-vtp-1000-shows-promising-safety-and-dose-dependent-effects-in-phase-1-celiac-disease-trial 2025-12-10T17:32:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/barinthus-bio-s-vtp-1000-shows-promising-safety-and-dose-dependent-effects-in-phase-1-celiac-disease-trial 2025-12-10T17:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/diakonos-oncology-secures-7-million-cprit-grant-to-advance-doc1021-dendritic-cell-therapy-in-refractory-melanoma 2025-12-10T17:32:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diakonos-oncology-secures-7-million-cprit-grant-to-advance-doc1021-dendritic-cell-therapy-in-refractory-melanoma 2025-12-10T17:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/ventus-therapeutics-doses-first-patient-in-phase-2-trial-of-vent-03-cgas-inhibitor-for-lupus 2025-12-10T17:32:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ventus-therapeutics-doses-first-patient-in-phase-2-trial-of-vent-03-cgas-inhibitor-for-lupus 2025-12-10T17:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/epilepsygtx-secures-33-million-series-a-to-advance-single-dose-gene-therapy-for-focal-refractory-epilepsy 2025-12-10T17:29:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epilepsygtx-secures-33-million-series-a-to-advance-single-dose-gene-therapy-for-focal-refractory-epilepsy 2025-12-10T17:29:56+00:00 hourly 0.9 https://trial.medpath.com/news/tildrakizumab-demonstrates-sustained-safety-profile-over-four-years-in-psoriatic-arthritis-extension-study 2025-12-10T17:29:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tildrakizumab-demonstrates-sustained-safety-profile-over-four-years-in-psoriatic-arthritis-extension-study 2025-12-10T17:29:53+00:00 hourly 0.9 https://trial.medpath.com/news/ontario-launches-fast-program-with-scemblix-as-first-priority-cancer-therapy-for-cml-patients 2025-12-10T17:28:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ontario-launches-fast-program-with-scemblix-as-first-priority-cancer-therapy-for-cml-patients 2025-12-10T17:28:50+00:00 hourly 0.9 https://trial.medpath.com/news/kazia-s-paxalisib-shows-promise-in-advanced-breast-cancer-with-76-tumor-reduction-and-immune-system-reinvigoration 2025-12-10T17:28:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kazia-s-paxalisib-shows-promise-in-advanced-breast-cancer-with-76-tumor-reduction-and-immune-system-reinvigoration 2025-12-10T17:28:01+00:00 hourly 0.9 https://trial.medpath.com/news/cellenkos-ck0804-regulatory-t-cell-therapy-shows-promise-in-jak-inhibitor-resistant-myelofibrosis 2025-12-10T17:27:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellenkos-ck0804-regulatory-t-cell-therapy-shows-promise-in-jak-inhibitor-resistant-myelofibrosis 2025-12-10T17:27:43+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-rsi-trial-reveals-etomidate-safer-than-ketamine-for-emergency-intubation 2025-12-10T17:27:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-rsi-trial-reveals-etomidate-safer-than-ketamine-for-emergency-intubation 2025-12-10T17:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-biosciences-submits-ind-for-first-in-class-kat6-7-dual-inhibitor-ide574-targeting-breast-and-lung-cancers 2025-12-10T17:27:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ideaya-biosciences-submits-ind-for-first-in-class-kat6-7-dual-inhibitor-ide574-targeting-breast-and-lung-cancers 2025-12-10T17:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/allonnia-raises-20-million-to-advance-biotechnology-platform-for-critical-mineral-recovery 2025-12-10T17:26:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allonnia-raises-20-million-to-advance-biotechnology-platform-for-critical-mineral-recovery 2025-12-10T17:26:31+00:00 hourly 0.9 https://trial.medpath.com/news/journey-medical-reports-positive-phase-1-results-for-emrosi-rosacea-treatment-showing-no-impact-on-microbiome 2025-12-10T17:26:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/journey-medical-reports-positive-phase-1-results-for-emrosi-rosacea-treatment-showing-no-impact-on-microbiome 2025-12-10T17:26:06+00:00 hourly 0.9 https://trial.medpath.com/news/nitinotes-initiates-pivotal-ease-trial-for-automated-endoscopic-sleeve-gastroplasty-system 2025-12-10T17:24:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nitinotes-initiates-pivotal-ease-trial-for-automated-endoscopic-sleeve-gastroplasty-system 2025-12-10T17:24:53+00:00 hourly 0.9 https://trial.medpath.com/news/trial-library-secures-10-million-series-a-to-democratize-clinical-trial-access-through-ai-enabled-community-platform 2025-12-10T17:24:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trial-library-secures-10-million-series-a-to-democratize-clinical-trial-access-through-ai-enabled-community-platform 2025-12-10T17:24:50+00:00 hourly 0.9 https://trial.medpath.com/news/hemostemix-receives-fda-support-for-basket-protocol-approach-in-stem-cell-therapy-development 2025-12-10T16:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemostemix-receives-fda-support-for-basket-protocol-approach-in-stem-cell-therapy-development 2025-12-10T16:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/blossomhill-therapeutics-secures-84-million-to-advance-first-in-class-egfr-inhibitor-for-lung-cancer 2025-12-10T13:37:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blossomhill-therapeutics-secures-84-million-to-advance-first-in-class-egfr-inhibitor-for-lung-cancer 2025-12-10T13:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/mmi-achieves-major-milestones-with-fda-clearance-for-robotic-microsurgical-instruments-and-new-cpt-reimbursement-code 2025-12-10T13:37:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mmi-achieves-major-milestones-with-fda-clearance-for-robotic-microsurgical-instruments-and-new-cpt-reimbursement-code 2025-12-10T13:37:11+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-drugs-show-no-increased-cancer-risk-in-large-meta-analysis-of-94000-patients 2025-12-10T13:37:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-drugs-show-no-increased-cancer-risk-in-large-meta-analysis-of-94000-patients 2025-12-10T13:37:02+00:00 hourly 0.9 https://trial.medpath.com/news/pharmala-biotech-advances-mdma-manufacturing-and-novel-ala-002-development-for-clinical-trials 2025-12-10T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmala-biotech-advances-mdma-manufacturing-and-novel-ala-002-development-for-clinical-trials 2025-12-10T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-biotherapeutics-partners-with-gsk-in-multi-target-cancer-drug-discovery-collaboration 2025-12-10T13:35:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-biotherapeutics-partners-with-gsk-in-multi-target-cancer-drug-discovery-collaboration 2025-12-10T13:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/physiomics-expands-biometrics-services-with-gardp-partnership-for-antibiotic-trial-optimization 2025-12-10T13:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/physiomics-expands-biometrics-services-with-gardp-partnership-for-antibiotic-trial-optimization 2025-12-10T13:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/cytiva-and-fida-biosystems-partner-to-accelerate-drug-discovery-through-combined-analytical-platform 2025-12-10T13:32:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytiva-and-fida-biosystems-partner-to-accelerate-drug-discovery-through-combined-analytical-platform 2025-12-10T13:32:26+00:00 hourly 0.9 https://trial.medpath.com/news/biotechnology-sector-experiences-market-volatility-following-december-2025-clinical-trial-results 2025-12-10T13:32:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotechnology-sector-experiences-market-volatility-following-december-2025-clinical-trial-results 2025-12-10T13:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-gene-therapy-for-wiskott-aldrich-syndrome-marking-historic-milestone-for-non-profit-drug-development 2025-12-10T13:32:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-gene-therapy-for-wiskott-aldrich-syndrome-marking-historic-milestone-for-non-profit-drug-development 2025-12-10T13:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/bendit-technologies-receives-fda-clearance-for-world-s-smallest-steerable-microcatheter 2025-12-10T13:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bendit-technologies-receives-fda-clearance-for-world-s-smallest-steerable-microcatheter 2025-12-10T13:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/vortex-launches-clinical-study-to-transform-cancer-monitoring-with-live-cell-liquid-biopsy-technology 2025-12-10T13:31:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vortex-launches-clinical-study-to-transform-cancer-monitoring-with-live-cell-liquid-biopsy-technology 2025-12-10T13:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/polpharma-biologics-partners-with-libbs-farmaceutica-to-bring-autoimmune-biosimilar-to-brazilian-market 2025-12-10T09:26:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polpharma-biologics-partners-with-libbs-farmaceutica-to-bring-autoimmune-biosimilar-to-brazilian-market 2025-12-10T09:26:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-gsk-s-b7-h3-targeted-adc-for-small-cell-lung-cancer 2025-12-10T09:25:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-gsk-s-b7-h3-targeted-adc-for-small-cell-lung-cancer 2025-12-10T09:25:29+00:00 hourly 0.9 https://trial.medpath.com/news/lunai-bioworks-launches-ai-driven-drug-discovery-programs-for-alcohol-use-disorder-and-parkinson-s-disease 2025-12-10T05:29:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lunai-bioworks-launches-ai-driven-drug-discovery-programs-for-alcohol-use-disorder-and-parkinson-s-disease 2025-12-10T05:29:15+00:00 hourly 0.9 https://trial.medpath.com/news/medicenna-s-mdna11-shows-promising-anti-tumor-activity-in-advanced-solid-tumors-at-esmo-io-congress-2025 2025-12-10T05:28:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicenna-s-mdna11-shows-promising-anti-tumor-activity-in-advanced-solid-tumors-at-esmo-io-congress-2025 2025-12-10T05:28:02+00:00 hourly 0.9 https://trial.medpath.com/news/cleveland-clinic-researchers-identify-distinct-biomarkers-for-predicting-car-t-cell-therapy-response-in-b-cell-lymphoma 2025-12-10T05:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleveland-clinic-researchers-identify-distinct-biomarkers-for-predicting-car-t-cell-therapy-response-in-b-cell-lymphoma 2025-12-10T05:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/uspto-introduces-subject-matter-eligibility-declarations-to-streamline-patent-protection-for-life-sciences-innovations 2025-12-10T05:27:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uspto-introduces-subject-matter-eligibility-declarations-to-streamline-patent-protection-for-life-sciences-innovations 2025-12-10T05:27:28+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-initiates-first-in-human-trial-of-ibi3011-novel-anti-il-1rap-monoclonal-antibody-for-gout-treatment 2025-12-10T05:26:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovent-initiates-first-in-human-trial-of-ibi3011-novel-anti-il-1rap-monoclonal-antibody-for-gout-treatment 2025-12-10T05:26:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reverses-course-on-nmn-reinstates-dietary-supplement-status-after-legal-challenge 2025-12-10T05:26:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-reverses-course-on-nmn-reinstates-dietary-supplement-status-after-legal-challenge 2025-12-10T05:26:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-gene-therapy-for-wiskott-aldrich-syndrome 2025-12-10T05:26:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-gene-therapy-for-wiskott-aldrich-syndrome 2025-12-10T05:26:30+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-provee-system-first-next-generation-prostatic-urethral-stent-for-benign-prostatic-hyperplasia 2025-12-10T05:24:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-provee-system-first-next-generation-prostatic-urethral-stent-for-benign-prostatic-hyperplasia 2025-12-10T05:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/akari-therapeutics-reports-promising-preclinical-data-for-aktx-101-in-k-ras-mutant-pancreatic-cancer 2025-12-10T03:21:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akari-therapeutics-reports-promising-preclinical-data-for-aktx-101-in-k-ras-mutant-pancreatic-cancer 2025-12-10T03:21:37+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-adds-duchenne-muscular-dystrophy-to-newborn-screening-panel-boosting-sarepta-s-market-prospects 2025-12-10T03:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hhs-adds-duchenne-muscular-dystrophy-to-newborn-screening-panel-boosting-sarepta-s-market-prospects 2025-12-10T03:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-launches-integrated-drug-development-platform-to-address-industry-fragmentation 2025-12-10T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-launches-integrated-drug-development-platform-to-address-industry-fragmentation 2025-12-10T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-adrabetadex-for-infantile-onset-niemann-pick-disease-type-c 2025-12-10T00:17:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-adrabetadex-for-infantile-onset-niemann-pick-disease-type-c 2025-12-10T00:17:56+00:00 hourly 0.9 https://trial.medpath.com/news/idorsia-s-dual-orexin-receptor-antagonist-wins-inaugural-prix-galien-bridges-award-for-insomnia-treatment-innovation 2025-12-10T00:17:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/idorsia-s-dual-orexin-receptor-antagonist-wins-inaugural-prix-galien-bridges-award-for-insomnia-treatment-innovation 2025-12-10T00:17:54+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-announces-6-billion-alabama-manufacturing-facility-for-glp-1-and-small-molecule-medicines 2025-12-10T00:17:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-announces-6-billion-alabama-manufacturing-facility-for-glp-1-and-small-molecule-medicines 2025-12-10T00:17:14+00:00 hourly 0.9 https://trial.medpath.com/news/hothouse-therapeutics-emerges-with-ps2-9m-to-revolutionize-plant-based-drug-manufacturing-using-ai 2025-12-10T00:17:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hothouse-therapeutics-emerges-with-ps2-9m-to-revolutionize-plant-based-drug-manufacturing-using-ai 2025-12-10T00:17:03+00:00 hourly 0.9 https://trial.medpath.com/news/magnus-medical-enrolls-first-patient-in-11-6m-dod-funded-trial-of-saint-therapy-for-postpartum-depression 2025-12-10T00:16:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/magnus-medical-enrolls-first-patient-in-11-6m-dod-funded-trial-of-saint-therapy-for-postpartum-depression 2025-12-10T00:16:54+00:00 hourly 0.9 https://trial.medpath.com/news/lexicon-pharmaceuticals-advances-multiple-late-stage-programs-with-key-2026-2027-milestones 2025-12-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexicon-pharmaceuticals-advances-multiple-late-stage-programs-with-key-2026-2027-milestones 2025-12-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cardiff-oncology-s-plk1-inhibitor-onvansertib-shows-promise-in-cmml-trial-and-advances-toward-phase-iii-in-colorectal-cancer 2025-12-09T21:39:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardiff-oncology-s-plk1-inhibitor-onvansertib-shows-promise-in-cmml-trial-and-advances-toward-phase-iii-in-colorectal-cancer 2025-12-09T21:39:14+00:00 hourly 0.9 https://trial.medpath.com/news/forensic-review-reveals-undisclosed-deaths-and-data-discrepancies-in-pfizer-covid-19-vaccine-trial 2025-12-09T21:35:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/forensic-review-reveals-undisclosed-deaths-and-data-discrepancies-in-pfizer-covid-19-vaccine-trial 2025-12-09T21:35:51+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-biontech-lp-8-1-adapted-covid-19-vaccine-receives-regulatory-approval-in-australia-and-new-zealand 2025-12-09T21:34:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-biontech-lp-8-1-adapted-covid-19-vaccine-receives-regulatory-approval-in-australia-and-new-zealand 2025-12-09T21:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/dexamethasone-prophylaxis-reduces-severe-neurotoxicity-in-car-t-therapy-without-compromising-efficacy 2025-12-09T21:34:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dexamethasone-prophylaxis-reduces-severe-neurotoxicity-in-car-t-therapy-without-compromising-efficacy 2025-12-09T21:34:25+00:00 hourly 0.9 https://trial.medpath.com/news/regenerative-patch-technologies-initiates-phase-iib-trial-for-stem-cell-based-retinal-implant-in-geographic-atrophy 2025-12-09T21:32:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regenerative-patch-technologies-initiates-phase-iib-trial-for-stem-cell-based-retinal-implant-in-geographic-atrophy 2025-12-09T21:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/cytoagents-to-present-cto1681-data-demonstrating-reduced-car-t-toxicity-without-compromising-efficacy-at-esmo-2025 2025-12-09T21:32:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytoagents-to-present-cto1681-data-demonstrating-reduced-car-t-toxicity-without-compromising-efficacy-at-esmo-2025 2025-12-09T21:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-and-ai-transform-rare-disease-clinical-trial-design-through-synthetic-control-arms 2025-12-09T21:30:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-data-and-ai-transform-rare-disease-clinical-trial-design-through-synthetic-control-arms 2025-12-09T21:30:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-nda-for-trn-257-first-once-nightly-low-sodium-oxybate-for-narcolepsy-and-idiopathic-hypersomnia 2025-12-09T21:29:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-nda-for-trn-257-first-once-nightly-low-sodium-oxybate-for-narcolepsy-and-idiopathic-hypersomnia 2025-12-09T21:29:32+00:00 hourly 0.9 https://trial.medpath.com/news/phanes-therapeutics-to-present-first-clinical-data-for-spevatamig-in-metastatic-pancreatic-cancer-at-asco-gi-2026 2025-12-09T21:29:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phanes-therapeutics-to-present-first-clinical-data-for-spevatamig-in-metastatic-pancreatic-cancer-at-asco-gi-2026 2025-12-09T21:29:09+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-researchers-develop-first-small-molecule-inhibitor-for-undruggable-cancer-protein-igf2bp3 2025-12-09T21:28:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucla-researchers-develop-first-small-molecule-inhibitor-for-undruggable-cancer-protein-igf2bp3 2025-12-09T21:28:32+00:00 hourly 0.9 https://trial.medpath.com/news/ensysce-biosciences-enrolls-first-patient-in-pivotal-phase-3-trial-for-abuse-resistant-opioid-pf614 2025-12-09T21:28:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensysce-biosciences-enrolls-first-patient-in-pivotal-phase-3-trial-for-abuse-resistant-opioid-pf614 2025-12-09T21:28:07+00:00 hourly 0.9 https://trial.medpath.com/news/celldex-advances-barzolvolimab-into-phase-3-trials-for-cold-urticaria-and-symptomatic-dermographism 2025-12-09T21:28:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celldex-advances-barzolvolimab-into-phase-3-trials-for-cold-urticaria-and-symptomatic-dermographism 2025-12-09T21:28:04+00:00 hourly 0.9 https://trial.medpath.com/news/pds-biotechnology-secures-new-japanese-patent-for-cancer-immunotherapy-pds0101-extending-protection-into-2040s 2025-12-09T21:28:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pds-biotechnology-secures-new-japanese-patent-for-cancer-immunotherapy-pds0101-extending-protection-into-2040s 2025-12-09T21:28:01+00:00 hourly 0.9 https://trial.medpath.com/news/airiver-medical-receives-fda-ide-approval-for-pivotal-trial-of-drug-coated-balloon-in-chronic-rhinosinusitis 2025-12-09T21:27:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/airiver-medical-receives-fda-ide-approval-for-pivotal-trial-of-drug-coated-balloon-in-chronic-rhinosinusitis 2025-12-09T21:27:21+00:00 hourly 0.9 https://trial.medpath.com/news/pulse-biosciences-advances-nanosecond-pulsed-field-ablation-technology-with-fda-approvals-for-cardiac-and-thyroid-cancer-studies 2025-12-09T21:27:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulse-biosciences-advances-nanosecond-pulsed-field-ablation-technology-with-fda-approvals-for-cardiac-and-thyroid-cancer-studies 2025-12-09T21:27:15+00:00 hourly 0.9 https://trial.medpath.com/news/new-mexico-accelerates-psilocybin-therapy-program-launch-to-december-2026-new-jersey-approves-hospital-based-pilot 2025-12-09T21:27:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-mexico-accelerates-psilocybin-therapy-program-launch-to-december-2026-new-jersey-approves-hospital-based-pilot 2025-12-09T21:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-first-postpartum-depression-specific-drug-zurzuvae 2025-12-09T21:26:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-first-postpartum-depression-specific-drug-zurzuvae 2025-12-09T21:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/enveda-advances-first-in-class-oral-therapy-env-294-to-phase-2-trials-for-atopic-dermatitis-and-asthma 2025-12-09T21:26:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enveda-advances-first-in-class-oral-therapy-env-294-to-phase-2-trials-for-atopic-dermatitis-and-asthma 2025-12-09T21:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/myriad-genetics-advances-ultrasensitive-mrd-testing-with-march-2026-clinical-launch 2025-12-09T17:42:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myriad-genetics-advances-ultrasensitive-mrd-testing-with-march-2026-clinical-launch 2025-12-09T17:42:31+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-secures-2-1-billion-deal-for-yaopharma-s-oral-glp-1-obesity-drug 2025-12-09T17:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-secures-2-1-billion-deal-for-yaopharma-s-oral-glp-1-obesity-drug 2025-12-09T17:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/epivax-and-fda-scientists-identify-immunogenicity-risks-in-generic-teriparatide-impurities 2025-12-09T17:41:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epivax-and-fda-scientists-identify-immunogenicity-risks-in-generic-teriparatide-impurities 2025-12-09T17:41:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-initiates-safety-review-of-infant-rsv-drugs-beyfortus-and-enflonsia-amid-kennedy-administration-scrutiny 2025-12-09T17:39:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-initiates-safety-review-of-infant-rsv-drugs-beyfortus-and-enflonsia-amid-kennedy-administration-scrutiny 2025-12-09T17:39:44+00:00 hourly 0.9 https://trial.medpath.com/news/sonothera-s-ultrasound-gene-therapy-achieves-65-normal-factor-viii-levels-in-hemophilia-a-primate-study 2025-12-09T17:38:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonothera-s-ultrasound-gene-therapy-achieves-65-normal-factor-viii-levels-in-hemophilia-a-primate-study 2025-12-09T17:38:02+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-secures-exclusive-rights-to-yaopharma-s-oral-glp-1-agonist-yp05002-in-2-1-billion-deal 2025-12-09T17:36:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-secures-exclusive-rights-to-yaopharma-s-oral-glp-1-agonist-yp05002-in-2-1-billion-deal 2025-12-09T17:36:56+00:00 hourly 0.9 https://trial.medpath.com/news/vincere-cancer-center-launches-clinical-study-for-syantra-s-immune-based-breast-cancer-screening-test 2025-12-09T17:34:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vincere-cancer-center-launches-clinical-study-for-syantra-s-immune-based-breast-cancer-screening-test 2025-12-09T17:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-narcolepsy-drug-oveporexton-shows-cognitive-benefits-in-phase-2-trial 2025-12-09T17:34:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-narcolepsy-drug-oveporexton-shows-cognitive-benefits-in-phase-2-trial 2025-12-09T17:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/probiogen-partners-with-spica-therapeutics-to-advance-first-in-class-anti-cd163-antibody-st101-for-cancer-immunotherapy 2025-12-09T17:34:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/probiogen-partners-with-spica-therapeutics-to-advance-first-in-class-anti-cd163-antibody-st101-for-cancer-immunotherapy 2025-12-09T17:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/phillips-medisize-showcases-advanced-inhaled-drug-delivery-platforms-at-ddl-2025-following-vectura-acquisition 2025-12-09T17:34:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phillips-medisize-showcases-advanced-inhaled-drug-delivery-platforms-at-ddl-2025-following-vectura-acquisition 2025-12-09T17:34:34+00:00 hourly 0.9 https://trial.medpath.com/news/verismo-s-novel-kir-car-platform-shows-superior-tumor-control-with-reduced-toxicity-in-preclinical-studies 2025-12-09T17:34:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verismo-s-novel-kir-car-platform-shows-superior-tumor-control-with-reduced-toxicity-in-preclinical-studies 2025-12-09T17:34:12+00:00 hourly 0.9 https://trial.medpath.com/news/create-medicines-initiates-first-in-class-frontline-hcc-trial-combining-in-vivo-car-therapy-mt-303-with-standard-immunotherapy 2025-12-09T17:34:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/create-medicines-initiates-first-in-class-frontline-hcc-trial-combining-in-vivo-car-therapy-mt-303-with-standard-immunotherapy 2025-12-09T17:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/destiny-ovarian01-phase-3-trial-launches-to-test-enhertu-as-first-line-maintenance-therapy-for-her2-expressing-ovarian-cancer 2025-12-09T17:34:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/destiny-ovarian01-phase-3-trial-launches-to-test-enhertu-as-first-line-maintenance-therapy-for-her2-expressing-ovarian-cancer 2025-12-09T17:34:07+00:00 hourly 0.9 https://trial.medpath.com/news/enterprise-therapeutics-etd001-shows-promise-as-novel-inhaled-enac-blocker-for-cystic-fibrosis-treatment 2025-12-09T17:33:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enterprise-therapeutics-etd001-shows-promise-as-novel-inhaled-enac-blocker-for-cystic-fibrosis-treatment 2025-12-09T17:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/xinnate-advances-tcp-25-for-epidermolysis-bullosa-with-fda-ind-approval-and-first-clinical-publication 2025-12-09T17:32:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xinnate-advances-tcp-25-for-epidermolysis-bullosa-with-fda-ind-approval-and-first-clinical-publication 2025-12-09T17:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/traction-trial-shows-tranexamic-acid-reduces-blood-transfusions-by-31-in-non-cardiac-surgery-without-increasing-clot-risk 2025-12-09T17:32:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/traction-trial-shows-tranexamic-acid-reduces-blood-transfusions-by-31-in-non-cardiac-surgery-without-increasing-clot-risk 2025-12-09T17:32:20+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-safety-data-confirms-long-term-tolerability-of-enjaymo-in-cold-agglutinin-disease-patients 2025-12-09T17:32:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-safety-data-confirms-long-term-tolerability-of-enjaymo-in-cold-agglutinin-disease-patients 2025-12-09T17:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/benchsci-extends-ai-partnership-with-merck-for-preclinical-disease-biology-research 2025-12-09T17:32:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/benchsci-extends-ai-partnership-with-merck-for-preclinical-disease-biology-research 2025-12-09T17:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/actimed-therapeutics-advances-novel-muscle-preserving-therapies-for-cancer-cachexia-and-glp-1-associated-muscle-loss 2025-12-09T17:30:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actimed-therapeutics-advances-novel-muscle-preserving-therapies-for-cancer-cachexia-and-glp-1-associated-muscle-loss 2025-12-09T17:30:04+00:00 hourly 0.9 https://trial.medpath.com/news/saol-therapeutics-secures-fda-type-a-meeting-to-advance-sl1009-for-rare-pediatric-mitochondrial-disease 2025-12-09T17:28:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saol-therapeutics-secures-fda-type-a-meeting-to-advance-sl1009-for-rare-pediatric-mitochondrial-disease 2025-12-09T17:28:58+00:00 hourly 0.9 https://trial.medpath.com/news/curis-reports-62-5-undetectable-mrd-rate-in-aml-triplet-therapy-study-at-ash-2025 2025-12-09T17:28:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curis-reports-62-5-undetectable-mrd-rate-in-aml-triplet-therapy-study-at-ash-2025 2025-12-09T17:28:11+00:00 hourly 0.9 https://trial.medpath.com/news/lee-s-pharmaceutical-acquires-staccato-inhalation-technology-platform-in-strategic-deal-with-ucb-partnership 2025-12-09T17:27:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lee-s-pharmaceutical-acquires-staccato-inhalation-technology-platform-in-strategic-deal-with-ucb-partnership 2025-12-09T17:27:32+00:00 hourly 0.9 https://trial.medpath.com/news/moleculin-advances-miracle-phase-3-aml-trial-with-78-enrollment-first-data-readout-expected-q1-2026 2025-12-09T17:27:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moleculin-advances-miracle-phase-3-aml-trial-with-78-enrollment-first-data-readout-expected-q1-2026 2025-12-09T17:27:29+00:00 hourly 0.9 https://trial.medpath.com/news/sibel-health-advances-digital-health-innovation-with-fda-recognition-for-cough-and-scratch-monitoring-technologies 2025-12-09T17:26:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sibel-health-advances-digital-health-innovation-with-fda-recognition-for-cough-and-scratch-monitoring-technologies 2025-12-09T17:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/seqtor-phase-iii-trial-shows-equivalent-survival-for-streptozotocin-5-fu-and-everolimus-sequencing-in-pancreatic-nets 2025-12-09T17:26:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seqtor-phase-iii-trial-shows-equivalent-survival-for-streptozotocin-5-fu-and-everolimus-sequencing-in-pancreatic-nets 2025-12-09T17:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/askbio-s-gene-therapies-ab-1005-and-ab-1002-receive-japan-s-pioneering-regenerative-medical-product-designation 2025-12-09T17:26:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/askbio-s-gene-therapies-ab-1005-and-ab-1002-receive-japan-s-pioneering-regenerative-medical-product-designation 2025-12-09T17:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/century-therapeutics-strengthens-board-with-biotech-veterans-to-advance-ipsc-cell-therapy-pipeline 2025-12-09T17:26:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/century-therapeutics-strengthens-board-with-biotech-veterans-to-advance-ipsc-cell-therapy-pipeline 2025-12-09T17:26:05+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-kisqali-shows-exceptional-long-term-efficacy-with-25-of-metastatic-breast-cancer-patients-remaining-progression-free-beyond-four-years 2025-12-09T17:26:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-kisqali-shows-exceptional-long-term-efficacy-with-25-of-metastatic-breast-cancer-patients-remaining-progression-free-beyond-four-years 2025-12-09T17:26:02+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-commits-1-7-billion-to-ai-driven-allergy-drug-discovery-partnership-with-relation-therapeutics 2025-12-09T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-commits-1-7-billion-to-ai-driven-allergy-drug-discovery-partnership-with-relation-therapeutics 2025-12-09T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/relation-therapeutics-secures-55-million-novartis-partnership-for-ai-driven-atopic-disease-target-discovery 2025-12-09T17:25:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/relation-therapeutics-secures-55-million-novartis-partnership-for-ai-driven-atopic-disease-target-discovery 2025-12-09T17:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/curifylabs-launches-3d-printed-veterinary-medicine-platform-to-address-pet-medication-compliance-challenges 2025-12-09T17:25:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curifylabs-launches-3d-printed-veterinary-medicine-platform-to-address-pet-medication-compliance-challenges 2025-12-09T17:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/federal-study-launches-to-evaluate-oregon-s-legal-psilocybin-program-for-substance-use-disorders 2025-12-09T17:25:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-study-launches-to-evaluate-oregon-s-legal-psilocybin-program-for-substance-use-disorders 2025-12-09T17:25:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-tightens-car-t-approval-standards-mandating-randomized-controlled-trials-for-future-therapies 2025-12-09T17:25:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-tightens-car-t-approval-standards-mandating-randomized-controlled-trials-for-future-therapies 2025-12-09T17:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/cannabix-technologies-marijuana-breath-test-device-passes-fcc-emissions-testing-advances-toward-u-s-and-canadian-market-entry 2025-12-09T14:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cannabix-technologies-marijuana-breath-test-device-passes-fcc-emissions-testing-advances-toward-u-s-and-canadian-market-entry 2025-12-09T14:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/generic-drug-industry-shows-strong-growth-as-biosimilar-launches-drive-revenue-expansion 2025-12-09T13:31:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/generic-drug-industry-shows-strong-growth-as-biosimilar-launches-drive-revenue-expansion 2025-12-09T13:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/senti-bio-s-senti-202-car-nk-therapy-achieves-50-response-rate-in-relapsed-refractory-aml-receives-fda-rmat-designation 2025-12-09T13:30:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senti-bio-s-senti-202-car-nk-therapy-achieves-50-response-rate-in-relapsed-refractory-aml-receives-fda-rmat-designation 2025-12-09T13:30:54+00:00 hourly 0.9 https://trial.medpath.com/news/ose-immunotherapeutics-expands-lusvertikimab-program-with-new-autoimmune-indications-in-2026-2028-strategic-plan 2025-12-09T13:30:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ose-immunotherapeutics-expands-lusvertikimab-program-with-new-autoimmune-indications-in-2026-2028-strategic-plan 2025-12-09T13:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/terns-pharmaceuticals-closes-747-5-million-public-offering-to-advance-bcr-abl-inhibitor-tern-701 2025-12-09T13:28:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/terns-pharmaceuticals-closes-747-5-million-public-offering-to-advance-bcr-abl-inhibitor-tern-701 2025-12-09T13:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/cepi-awards-16m-to-korean-consortium-for-first-ever-sfts-mrna-vaccine-development 2025-12-09T13:28:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cepi-awards-16m-to-korean-consortium-for-first-ever-sfts-mrna-vaccine-development 2025-12-09T13:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/enterome-s-eo2463-achieves-100-response-rate-in-follicular-lymphoma-phase-2-trial 2025-12-09T13:28:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enterome-s-eo2463-achieves-100-response-rate-in-follicular-lymphoma-phase-2-trial 2025-12-09T13:28:37+00:00 hourly 0.9 https://trial.medpath.com/news/dizal-reports-promising-hematology-data-at-ash-2025-with-jak1-inhibitor-golidocitinib-and-dual-btk-lyn-inhibitor-birelentinib 2025-12-09T13:27:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dizal-reports-promising-hematology-data-at-ash-2025-with-jak1-inhibitor-golidocitinib-and-dual-btk-lyn-inhibitor-birelentinib 2025-12-09T13:27:47+00:00 hourly 0.9 https://trial.medpath.com/news/precision-immunotherapy-shows-promise-for-sepsis-treatment-through-targeted-patient-selection 2025-12-09T13:27:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-immunotherapy-shows-promise-for-sepsis-treatment-through-targeted-patient-selection 2025-12-09T13:27:39+00:00 hourly 0.9 https://trial.medpath.com/news/sk-biopharmaceuticals-cenobamate-and-solriamfetol-receive-nmpa-approval-for-china-market 2025-12-09T13:26:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-biopharmaceuticals-cenobamate-and-solriamfetol-receive-nmpa-approval-for-china-market 2025-12-09T13:26:29+00:00 hourly 0.9 https://trial.medpath.com/news/scancell-s-iscib1-shows-74-progression-free-survival-at-16-months-in-advanced-melanoma-phase-2-trial 2025-12-09T13:26:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scancell-s-iscib1-shows-74-progression-free-survival-at-16-months-in-advanced-melanoma-phase-2-trial 2025-12-09T13:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/cellular-origins-raises-40m-series-a-to-scale-cell-therapy-manufacturing-platform 2025-12-09T13:25:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellular-origins-raises-40m-series-a-to-scale-cell-therapy-manufacturing-platform 2025-12-09T13:25:37+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-oxford-launches-world-s-first-phase-ii-nipah-virus-vaccine-trial-in-bangladesh 2025-12-09T13:25:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-oxford-launches-world-s-first-phase-ii-nipah-virus-vaccine-trial-in-bangladesh 2025-12-09T13:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/castle-biosciences-gene-expression-tests-show-superior-survival-prediction-in-melanoma-patients 2025-12-09T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/castle-biosciences-gene-expression-tests-show-superior-survival-prediction-in-melanoma-patients 2025-12-09T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/guinea-bissau-suspends-trump-backed-hepatitis-b-vaccine-study-amid-ethical-concerns 2025-12-09T09:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guinea-bissau-suspends-trump-backed-hepatitis-b-vaccine-study-amid-ethical-concerns 2025-12-09T09:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/global-pharma-companies-seek-r-d-efficiency-lessons-from-china-s-clinical-trial-success 2025-12-09T09:25:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-pharma-companies-seek-r-d-efficiency-lessons-from-china-s-clinical-trial-success 2025-12-09T09:25:31+00:00 hourly 0.9 https://trial.medpath.com/news/fox-chase-cancer-center-demonstrates-safe-home-monitoring-for-t-cell-redirecting-therapies 2025-12-09T09:25:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fox-chase-cancer-center-demonstrates-safe-home-monitoring-for-t-cell-redirecting-therapies 2025-12-09T09:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/greenyn-biotechnology-s-insumate-r-mcirbp-19-bitter-melon-peptide-achieves-triple-certification-for-metabolic-health 2025-12-09T09:24:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/greenyn-biotechnology-s-insumate-r-mcirbp-19-bitter-melon-peptide-achieves-triple-certification-for-metabolic-health 2025-12-09T09:24:49+00:00 hourly 0.9 https://trial.medpath.com/news/mercury-bio-partners-with-meta-flux-to-accelerate-cns-therapeutics-using-ai-powered-disease-modeling-and-novel-delivery-platform 2025-12-09T05:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mercury-bio-partners-with-meta-flux-to-accelerate-cns-therapeutics-using-ai-powered-disease-modeling-and-novel-delivery-platform 2025-12-09T05:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/genfit-s-g1090n-shows-promising-phase-1-results-for-acute-on-chronic-liver-failure-treatment 2025-12-09T05:28:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genfit-s-g1090n-shows-promising-phase-1-results-for-acute-on-chronic-liver-failure-treatment 2025-12-09T05:28:16+00:00 hourly 0.9 https://trial.medpath.com/news/ptab-pendulum-swings-back-as-patent-enforcement-landscape-shifts-toward-stronger-ip-protection 2025-12-09T05:26:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ptab-pendulum-swings-back-as-patent-enforcement-landscape-shifts-toward-stronger-ip-protection 2025-12-09T05:26:34+00:00 hourly 0.9 https://trial.medpath.com/news/kymera-therapeutics-closes-upsized-602-million-public-offering-to-advance-targeted-protein-degradation-pipeline 2025-12-09T05:26:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kymera-therapeutics-closes-upsized-602-million-public-offering-to-advance-targeted-protein-degradation-pipeline 2025-12-09T05:26:29+00:00 hourly 0.9 https://trial.medpath.com/news/vera-therapeutics-raises-300-million-in-public-offering-to-advance-immunologic-disease-pipeline 2025-12-09T05:26:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vera-therapeutics-raises-300-million-in-public-offering-to-advance-immunologic-disease-pipeline 2025-12-09T05:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/pathai-expands-european-presence-with-major-academic-medical-center-partnerships-for-ai-powered-pathology-solutions 2025-12-09T01:35:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pathai-expands-european-presence-with-major-academic-medical-center-partnerships-for-ai-powered-pathology-solutions 2025-12-09T01:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/casi-pharmaceuticals-cid-103-shows-73-response-rate-in-phase-1-immune-thrombocytopenia-trial 2025-12-09T01:35:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/casi-pharmaceuticals-cid-103-shows-73-response-rate-in-phase-1-immune-thrombocytopenia-trial 2025-12-09T01:35:03+00:00 hourly 0.9 https://trial.medpath.com/news/aleta-001-shows-promise-in-phase-i-ii-trial-for-relapsed-b-cell-malignancies-after-car-t-therapy 2025-12-09T01:33:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aleta-001-shows-promise-in-phase-i-ii-trial-for-relapsed-b-cell-malignancies-after-car-t-therapy 2025-12-09T01:33:57+00:00 hourly 0.9 https://trial.medpath.com/news/assembly-biosciences-herpes-drugs-show-98-reduction-in-viral-shedding-in-phase-i-studies 2025-12-09T01:33:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/assembly-biosciences-herpes-drugs-show-98-reduction-in-viral-shedding-in-phase-i-studies 2025-12-09T01:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/qihan-biotech-initiates-phase-i-iia-trial-of-off-the-shelf-car-t-therapy-for-refractory-lupus 2025-12-09T01:33:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qihan-biotech-initiates-phase-i-iia-trial-of-off-the-shelf-car-t-therapy-for-refractory-lupus 2025-12-09T01:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/wave-life-sciences-wve-007-shows-superior-fat-loss-in-phase-1-trial-stock-surges-146 2025-12-09T01:31:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wave-life-sciences-wve-007-shows-superior-fat-loss-in-phase-1-trial-stock-surges-146 2025-12-09T01:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-mrna-flu-vaccine-shows-30-superior-effectiveness-in-phase-3-trial 2025-12-09T01:31:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-s-mrna-flu-vaccine-shows-30-superior-effectiveness-in-phase-3-trial 2025-12-09T01:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/imviva-biotech-reports-promising-car-t-cell-therapy-data-at-ash-2025-meeting 2025-12-09T01:31:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imviva-biotech-reports-promising-car-t-cell-therapy-data-at-ash-2025-meeting 2025-12-09T01:31:04+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-mrna-vaccines-show-promise-in-boosting-cancer-immunotherapy-effectiveness 2025-12-09T01:30:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/covid-19-mrna-vaccines-show-promise-in-boosting-cancer-immunotherapy-effectiveness 2025-12-09T01:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/morning-immunotherapy-administration-reduces-death-risk-by-63-in-small-cell-lung-cancer-patients 2025-12-09T01:30:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/morning-immunotherapy-administration-reduces-death-risk-by-63-in-small-cell-lung-cancer-patients 2025-12-09T01:30:53+00:00 hourly 0.9 https://trial.medpath.com/news/world-first-base-edited-car-t-therapy-shows-64-disease-free-survival-in-previously-untreatable-t-cell-leukemia 2025-12-09T01:29:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-first-base-edited-car-t-therapy-shows-64-disease-free-survival-in-previously-untreatable-t-cell-leukemia 2025-12-09T01:29:37+00:00 hourly 0.9 https://trial.medpath.com/news/anova-achieves-rapid-clinical-trial-enrollment-using-ai-powered-platform-enrolling-550-cancer-patients-in-six-months 2025-12-09T01:28:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anova-achieves-rapid-clinical-trial-enrollment-using-ai-powered-platform-enrolling-550-cancer-patients-in-six-months 2025-12-09T01:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/hk-innoen-s-k-cab-receives-brazilian-gmp-certification-advances-global-market-expansion 2025-12-09T01:27:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hk-innoen-s-k-cab-receives-brazilian-gmp-certification-advances-global-market-expansion 2025-12-09T01:27:33+00:00 hourly 0.9 https://trial.medpath.com/news/hikma-launches-first-room-temperature-stable-vancomycin-injection-for-critical-sepsis-treatment 2025-12-09T01:26:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hikma-launches-first-room-temperature-stable-vancomycin-injection-for-critical-sepsis-treatment 2025-12-09T01:26:04+00:00 hourly 0.9 https://trial.medpath.com/news/jackson-laboratory-receives-30-million-arpa-h-award-to-develop-ai-powered-virtual-hearts-for-drug-safety-testing 2025-12-09T01:26:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jackson-laboratory-receives-30-million-arpa-h-award-to-develop-ai-powered-virtual-hearts-for-drug-safety-testing 2025-12-09T01:26:01+00:00 hourly 0.9 https://trial.medpath.com/news/opna-bio-s-zavabresib-receives-fda-orphan-drug-designation-for-myelofibrosis-treatment 2025-12-08T21:39:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opna-bio-s-zavabresib-receives-fda-orphan-drug-designation-for-myelofibrosis-treatment 2025-12-08T21:39:16+00:00 hourly 0.9 https://trial.medpath.com/news/restem-initiates-first-in-human-trial-of-umbilical-cell-therapy-for-facioscapulohumeral-muscular-dystrophy 2025-12-08T21:38:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/restem-initiates-first-in-human-trial-of-umbilical-cell-therapy-for-facioscapulohumeral-muscular-dystrophy 2025-12-08T21:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/seabelife-partners-with-unither-pharmaceuticals-to-advance-sbl03-ophthalmic-formulation-for-retinal-degenerative-disorders 2025-12-08T21:35:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seabelife-partners-with-unither-pharmaceuticals-to-advance-sbl03-ophthalmic-formulation-for-retinal-degenerative-disorders 2025-12-08T21:35:17+00:00 hourly 0.9 https://trial.medpath.com/news/nfl-biosciences-raises-efficacy-targets-for-smoking-cessation-drug-candidates-with-novel-mechanism-discovery 2025-12-08T21:34:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nfl-biosciences-raises-efficacy-targets-for-smoking-cessation-drug-candidates-with-novel-mechanism-discovery 2025-12-08T21:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/geovax-s-gedeptin-shows-disease-stability-in-heavily-pretreated-head-and-neck-cancer-patients 2025-12-08T21:33:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geovax-s-gedeptin-shows-disease-stability-in-heavily-pretreated-head-and-neck-cancer-patients 2025-12-08T21:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/us-government-backs-hikma-s-supreme-court-appeal-in-vascepa-generic-patent-dispute 2025-12-08T21:33:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-government-backs-hikma-s-supreme-court-appeal-in-vascepa-generic-patent-dispute 2025-12-08T21:33:13+00:00 hourly 0.9 https://trial.medpath.com/news/routine-blood-test-predicts-car-t-therapy-success-in-non-hodgkin-lymphoma-patients 2025-12-08T21:31:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/routine-blood-test-predicts-car-t-therapy-success-in-non-hodgkin-lymphoma-patients 2025-12-08T21:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/reveal-genomics-unveils-breakthrough-cns-progression-score-for-her2-breast-cancer-brain-metastasis-prediction-at-sabcs-2025 2025-12-08T21:30:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reveal-genomics-unveils-breakthrough-cns-progression-score-for-her2-breast-cancer-brain-metastasis-prediction-at-sabcs-2025 2025-12-08T21:30:43+00:00 hourly 0.9 https://trial.medpath.com/news/novel-astatine-211-targeted-alpha-therapy-shows-promise-for-radioactive-iodine-refractory-thyroid-cancer 2025-12-08T21:30:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-astatine-211-targeted-alpha-therapy-shows-promise-for-radioactive-iodine-refractory-thyroid-cancer 2025-12-08T21:30:07+00:00 hourly 0.9 https://trial.medpath.com/news/subcutaneous-cevostamab-shows-promise-in-relapsed-refractory-multiple-myeloma-with-38-8-response-rate 2025-12-08T21:29:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/subcutaneous-cevostamab-shows-promise-in-relapsed-refractory-multiple-myeloma-with-38-8-response-rate 2025-12-08T21:29:56+00:00 hourly 0.9 https://trial.medpath.com/news/saskatchewan-adds-merck-s-capvaxive-to-publicly-funded-adult-immunization-program 2025-12-08T21:29:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saskatchewan-adds-merck-s-capvaxive-to-publicly-funded-adult-immunization-program 2025-12-08T21:29:15+00:00 hourly 0.9 https://trial.medpath.com/news/terns-tern-701-shows-superior-molecular-response-rates-in-chronic-myeloid-leukemia-challenging-novartis-scemblix-dominance 2025-12-08T21:29:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/terns-tern-701-shows-superior-molecular-response-rates-in-chronic-myeloid-leukemia-challenging-novartis-scemblix-dominance 2025-12-08T21:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/eczema-drug-development-pipeline-surges-with-100-companies-advancing-novel-therapies 2025-12-08T21:28:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eczema-drug-development-pipeline-surges-with-100-companies-advancing-novel-therapies 2025-12-08T21:28:23+00:00 hourly 0.9 https://trial.medpath.com/news/kamada-discontinues-phase-3-inhaled-aat-trial-following-futility-analysis-maintains-strong-financial-outlook 2025-12-08T21:27:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kamada-discontinues-phase-3-inhaled-aat-trial-following-futility-analysis-maintains-strong-financial-outlook 2025-12-08T21:27:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-enhanced-omnipod-5-algorithm-with-lower-glucose-target-for-improved-diabetes-management 2025-12-08T21:26:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-enhanced-omnipod-5-algorithm-with-lower-glucose-target-for-improved-diabetes-management 2025-12-08T21:26:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-bioequivalent-injectable-antiemetic-solution-for-veterinary-use 2025-12-08T21:26:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-bioequivalent-injectable-antiemetic-solution-for-veterinary-use 2025-12-08T21:26:28+00:00 hourly 0.9 https://trial.medpath.com/news/intellicule-receives-217941-nih-grant-to-develop-ai-powered-cryo-em-software-for-drug-discovery 2025-12-08T21:26:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intellicule-receives-217941-nih-grant-to-develop-ai-powered-cryo-em-software-for-drug-discovery 2025-12-08T21:26:25+00:00 hourly 0.9 https://trial.medpath.com/news/baylor-college-of-medicine-leads-21m-ai-driven-cardiac-drug-safety-initiative-to-reduce-clinical-trial-failures 2025-12-08T21:25:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/baylor-college-of-medicine-leads-21m-ai-driven-cardiac-drug-safety-initiative-to-reduce-clinical-trial-failures 2025-12-08T21:25:42+00:00 hourly 0.9 https://trial.medpath.com/news/spinogenix-s-tazbentetol-shows-rapid-cognitive-improvement-in-alzheimer-s-disease-phase-2-trial 2025-12-08T21:24:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spinogenix-s-tazbentetol-shows-rapid-cognitive-improvement-in-alzheimer-s-disease-phase-2-trial 2025-12-08T21:24:35+00:00 hourly 0.9 https://trial.medpath.com/news/elacestrant-combination-therapy-shows-promising-progression-free-survival-results-in-er-metastatic-breast-cancer 2025-12-08T17:48:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elacestrant-combination-therapy-shows-promising-progression-free-survival-results-in-er-metastatic-breast-cancer 2025-12-08T17:48:07+00:00 hourly 0.9 https://trial.medpath.com/news/ernexa-therapeutics-advances-erna-101-cell-therapy-for-ovarian-cancer-following-fda-alignment-and-promising-preclinical-data 2025-12-08T17:47:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ernexa-therapeutics-advances-erna-101-cell-therapy-for-ovarian-cancer-following-fda-alignment-and-promising-preclinical-data 2025-12-08T17:47:17+00:00 hourly 0.9 https://trial.medpath.com/news/pan-cancer-t-secures-eur10-million-to-advance-tcr-t-cell-therapy-for-triple-negative-breast-cancer 2025-12-08T17:47:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pan-cancer-t-secures-eur10-million-to-advance-tcr-t-cell-therapy-for-triple-negative-breast-cancer 2025-12-08T17:47:15+00:00 hourly 0.9 https://trial.medpath.com/news/pillar-biosciences-and-astrazeneca-expand-liquid-biopsy-partnership-to-china-amid-high-cancer-burden 2025-12-08T17:45:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pillar-biosciences-and-astrazeneca-expand-liquid-biopsy-partnership-to-china-amid-high-cancer-burden 2025-12-08T17:45:27+00:00 hourly 0.9 https://trial.medpath.com/news/autolus-reports-promising-car-t-results-for-severe-lupus-and-pediatric-leukemia-at-ash-2025 2025-12-08T17:45:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/autolus-reports-promising-car-t-results-for-severe-lupus-and-pediatric-leukemia-at-ash-2025 2025-12-08T17:45:19+00:00 hourly 0.9 https://trial.medpath.com/news/march-biosciences-reports-100-complete-response-rate-with-mb-105-car-t-therapy-in-relapsed-t-cell-lymphoma 2025-12-08T17:45:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/march-biosciences-reports-100-complete-response-rate-with-mb-105-car-t-therapy-in-relapsed-t-cell-lymphoma 2025-12-08T17:45:16+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-terminates-five-year-cancer-partnership-with-ideaya-biosciences-returns-two-synthetic-lethality-programs 2025-12-08T17:44:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-terminates-five-year-cancer-partnership-with-ideaya-biosciences-returns-two-synthetic-lethality-programs 2025-12-08T17:44:26+00:00 hourly 0.9 https://trial.medpath.com/news/vyome-s-vt-1953-achieves-primary-endpoints-in-phase-2-trial-for-malignant-fungating-wounds 2025-12-08T17:43:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vyome-s-vt-1953-achieves-primary-endpoints-in-phase-2-trial-for-malignant-fungating-wounds 2025-12-08T17:43:33+00:00 hourly 0.9 https://trial.medpath.com/news/novel-car-t-regulatory-cell-therapy-shows-promise-in-refractory-rheumatoid-arthritis 2025-12-08T17:43:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-car-t-regulatory-cell-therapy-shows-promise-in-refractory-rheumatoid-arthritis 2025-12-08T17:43:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-extends-review-timeline-for-agios-mitapivat-thalassemia-application-beyond-pdufa-date 2025-12-08T17:37:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-extends-review-timeline-for-agios-mitapivat-thalassemia-application-beyond-pdufa-date 2025-12-08T17:37:04+00:00 hourly 0.9 https://trial.medpath.com/news/alr-technologies-prepares-january-2026-relaunch-of-glucurve-pet-cgm-following-successful-manufacturing-tests 2025-12-08T17:37:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alr-technologies-prepares-january-2026-relaunch-of-glucurve-pet-cgm-following-successful-manufacturing-tests 2025-12-08T17:37:02+00:00 hourly 0.9 https://trial.medpath.com/news/mirum-pharmaceuticals-acquires-bluejay-therapeutics-for-620m-to-advance-breakthrough-hdv-treatment 2025-12-08T17:36:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mirum-pharmaceuticals-acquires-bluejay-therapeutics-for-620m-to-advance-breakthrough-hdv-treatment 2025-12-08T17:36:56+00:00 hourly 0.9 https://trial.medpath.com/news/biomx-discontinues-phase-2b-cystic-fibrosis-trial-due-to-safety-concerns 2025-12-08T17:36:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomx-discontinues-phase-2b-cystic-fibrosis-trial-due-to-safety-concerns 2025-12-08T17:36:02+00:00 hourly 0.9 https://trial.medpath.com/news/fate-therapeutics-reports-promising-phase-1-results-for-off-the-shelf-car-t-therapy-ft819-in-systemic-lupus-erythematosus 2025-12-08T17:35:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fate-therapeutics-reports-promising-phase-1-results-for-off-the-shelf-car-t-therapy-ft819-in-systemic-lupus-erythematosus 2025-12-08T17:35:41+00:00 hourly 0.9 https://trial.medpath.com/news/scottish-medicines-consortium-approves-rybrevant-combination-for-first-line-egfr-exon-20-insertion-nsclc-treatment 2025-12-08T17:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scottish-medicines-consortium-approves-rybrevant-combination-for-first-line-egfr-exon-20-insertion-nsclc-treatment 2025-12-08T17:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/cytomed-therapeutics-partners-with-malaysian-medical-center-for-first-in-human-gamma-delta-t-cell-cancer-trial 2025-12-08T17:32:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytomed-therapeutics-partners-with-malaysian-medical-center-for-first-in-human-gamma-delta-t-cell-cancer-trial 2025-12-08T17:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/citryll-doses-first-patient-in-phase-iia-trial-of-cit-013-for-hidradenitis-suppurativa 2025-12-08T17:32:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/citryll-doses-first-patient-in-phase-iia-trial-of-cit-013-for-hidradenitis-suppurativa 2025-12-08T17:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/tutor-phase-1-trial-combines-stereotactic-radiosurgery-with-triple-her2-targeted-therapy-for-brain-metastases 2025-12-08T17:31:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tutor-phase-1-trial-combines-stereotactic-radiosurgery-with-triple-her2-targeted-therapy-for-brain-metastases 2025-12-08T17:31:50+00:00 hourly 0.9 https://trial.medpath.com/news/solid-biosciences-advances-gene-therapy-pipeline-with-next-generation-capsid-technology-and-regulatory-milestones 2025-12-08T17:31:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solid-biosciences-advances-gene-therapy-pipeline-with-next-generation-capsid-technology-and-regulatory-milestones 2025-12-08T17:31:11+00:00 hourly 0.9 https://trial.medpath.com/news/convergen-raises-10-million-to-advance-novel-trimtac-platform-targeting-neurodegenerative-disease-protein-aggregates 2025-12-08T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/convergen-raises-10-million-to-advance-novel-trimtac-platform-targeting-neurodegenerative-disease-protein-aggregates 2025-12-08T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/recordati-presents-breakthrough-ai-technology-and-real-world-evidence-for-castleman-disease-at-ash-2025 2025-12-08T17:30:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recordati-presents-breakthrough-ai-technology-and-real-world-evidence-for-castleman-disease-at-ash-2025 2025-12-08T17:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/ss-innovations-files-510-k-submission-for-ssi-mantra-surgical-robot-with-fda 2025-12-08T17:30:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ss-innovations-files-510-k-submission-for-ssi-mantra-surgical-robot-with-fda 2025-12-08T17:30:27+00:00 hourly 0.9 https://trial.medpath.com/news/vaxcyte-initiates-phase-3-trial-for-vax-31-pneumococcal-vaccine-with-potential-to-expand-disease-coverage-by-34 2025-12-08T17:29:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaxcyte-initiates-phase-3-trial-for-vax-31-pneumococcal-vaccine-with-potential-to-expand-disease-coverage-by-34 2025-12-08T17:29:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-updates-expanded-access-guidance-to-streamline-investigational-drug-access-for-patients 2025-12-08T17:29:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-updates-expanded-access-guidance-to-streamline-investigational-drug-access-for-patients 2025-12-08T17:29:34+00:00 hourly 0.9 https://trial.medpath.com/news/moleculin-partners-with-cic-biomagune-to-evaluate-annamycin-for-glioblastoma-treatment 2025-12-08T17:29:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moleculin-partners-with-cic-biomagune-to-evaluate-annamycin-for-glioblastoma-treatment 2025-12-08T17:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/ouro-medicines-gamgertamig-receives-second-fda-orphan-drug-designation-for-immune-thrombocytopenia 2025-12-08T17:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ouro-medicines-gamgertamig-receives-second-fda-orphan-drug-designation-for-immune-thrombocytopenia 2025-12-08T17:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-s-rec-4881-shows-durable-polyp-reduction-in-familial-adenomatous-polyposis-phase-2-trial 2025-12-08T17:28:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-s-rec-4881-shows-durable-polyp-reduction-in-familial-adenomatous-polyposis-phase-2-trial 2025-12-08T17:28:58+00:00 hourly 0.9 https://trial.medpath.com/news/spinogenix-s-tazbentetol-shows-rapid-cognitive-improvement-in-phase-2a-alzheimer-s-trial 2025-12-08T17:28:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spinogenix-s-tazbentetol-shows-rapid-cognitive-improvement-in-phase-2a-alzheimer-s-trial 2025-12-08T17:28:55+00:00 hourly 0.9 https://trial.medpath.com/news/agora-open-science-trust-selects-m4k2009-as-lead-candidate-for-rare-pediatric-brain-cancer-treatment 2025-12-08T17:28:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agora-open-science-trust-selects-m4k2009-as-lead-candidate-for-rare-pediatric-brain-cancer-treatment 2025-12-08T17:28:10+00:00 hourly 0.9 https://trial.medpath.com/news/galmed-s-aramchol-shows-promise-in-hepatocellular-carcinoma-combination-therapy-prompting-phase-1-2-trial 2025-12-08T17:28:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galmed-s-aramchol-shows-promise-in-hepatocellular-carcinoma-combination-therapy-prompting-phase-1-2-trial 2025-12-08T17:28:04+00:00 hourly 0.9 https://trial.medpath.com/news/dyne-therapeutics-advances-duchenne-drug-to-regulatory-filing-as-biotech-stocks-surge-on-promising-trial-data 2025-12-08T17:28:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyne-therapeutics-advances-duchenne-drug-to-regulatory-filing-as-biotech-stocks-surge-on-promising-trial-data 2025-12-08T17:28:01+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-s-retatrutide-achieves-record-28-7-weight-loss-in-phase-3-trial-despite-high-discontinuation-rates 2025-12-08T17:27:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-s-retatrutide-achieves-record-28-7-weight-loss-in-phase-3-trial-despite-high-discontinuation-rates 2025-12-08T17:27:53+00:00 hourly 0.9 https://trial.medpath.com/news/pierre-fabre-s-tabelecleucel-shows-47-7-response-rate-in-phase-3-trial-for-rare-post-transplant-cancer 2025-12-08T17:27:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pierre-fabre-s-tabelecleucel-shows-47-7-response-rate-in-phase-3-trial-for-rare-post-transplant-cancer 2025-12-08T17:27:35+00:00 hourly 0.9 https://trial.medpath.com/news/puretech-health-shares-rise-following-fda-meeting-after-phase-ii-trial-completion 2025-12-08T17:26:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/puretech-health-shares-rise-following-fda-meeting-after-phase-ii-trial-completion 2025-12-08T17:26:54+00:00 hourly 0.9 https://trial.medpath.com/news/glyconex-partners-with-change-cure-to-advance-first-in-class-hmgb1-targeted-antibody-for-frontotemporal-lobar-degeneration 2025-12-08T17:26:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glyconex-partners-with-change-cure-to-advance-first-in-class-hmgb1-targeted-antibody-for-frontotemporal-lobar-degeneration 2025-12-08T17:26:12+00:00 hourly 0.9 https://trial.medpath.com/news/sana-biotechnology-achieves-breakthrough-in-in-vivo-gene-editing-of-hematopoietic-stem-cells-using-fusogen-technology 2025-12-08T17:26:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sana-biotechnology-achieves-breakthrough-in-in-vivo-gene-editing-of-hematopoietic-stem-cells-using-fusogen-technology 2025-12-08T17:26:09+00:00 hourly 0.9 https://trial.medpath.com/news/her2-amplification-linked-to-worse-outcomes-in-first-line-metastatic-colorectal-cancer-treatment 2025-12-08T17:26:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/her2-amplification-linked-to-worse-outcomes-in-first-line-metastatic-colorectal-cancer-treatment 2025-12-08T17:26:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-ide-approval-for-first-synthetic-corneal-endothelial-layer-to-treat-chronic-corneal-edema 2025-12-08T17:25:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-ide-approval-for-first-synthetic-corneal-endothelial-layer-to-treat-chronic-corneal-edema 2025-12-08T17:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/avacta-s-faridoxorubicin-shows-promising-tumor-shrinkage-in-salivary-gland-cancer-phase-1b-trial 2025-12-08T17:25:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avacta-s-faridoxorubicin-shows-promising-tumor-shrinkage-in-salivary-gland-cancer-phase-1b-trial 2025-12-08T17:25:27+00:00 hourly 0.9 https://trial.medpath.com/news/wellgistics-health-launches-diabetes-drug-brenzavvy-through-6500-pharmacy-network-targeting-cost-effective-sglt-2-treatment 2025-12-08T17:25:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wellgistics-health-launches-diabetes-drug-brenzavvy-through-6500-pharmacy-network-targeting-cost-effective-sglt-2-treatment 2025-12-08T17:25:24+00:00 hourly 0.9 https://trial.medpath.com/news/neuropace-files-fda-application-for-rns-system-expansion-to-treat-drug-resistant-generalized-epilepsy 2025-12-08T17:25:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuropace-files-fda-application-for-rns-system-expansion-to-treat-drug-resistant-generalized-epilepsy 2025-12-08T17:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/dechra-receives-fda-approval-for-emeprev-injectable-solution-first-bioequivalent-maropitant-for-veterinary-use 2025-12-08T17:25:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dechra-receives-fda-approval-for-emeprev-injectable-solution-first-bioequivalent-maropitant-for-veterinary-use 2025-12-08T17:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/cirrhosis-reshapes-immune-microenvironment-limiting-hepatocellular-carcinoma-immunotherapy-efficacy 2025-12-08T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cirrhosis-reshapes-immune-microenvironment-limiting-hepatocellular-carcinoma-immunotherapy-efficacy 2025-12-08T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ose-immunotherapeutics-regains-control-of-abbv-230-early-development-in-strategic-partnership-amendment-with-abbvie 2025-12-08T13:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ose-immunotherapeutics-regains-control-of-abbv-230-early-development-in-strategic-partnership-amendment-with-abbvie 2025-12-08T13:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/dyne-therapeutics-reports-breakthrough-results-for-duchenne-muscular-dystrophy-gene-therapy 2025-12-08T13:32:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyne-therapeutics-reports-breakthrough-results-for-duchenne-muscular-dystrophy-gene-therapy 2025-12-08T13:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/scancell-s-iscib1-immunotherapy-shows-74-progression-free-survival-in-phase-ii-melanoma-trial 2025-12-08T13:30:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scancell-s-iscib1-immunotherapy-shows-74-progression-free-survival-in-phase-ii-melanoma-trial 2025-12-08T13:30:36+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-secures-370m-licensing-deal-for-immutep-s-cancer-immunotherapy 2025-12-08T13:29:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-reddy-s-secures-370m-licensing-deal-for-immutep-s-cancer-immunotherapy 2025-12-08T13:29:27+00:00 hourly 0.9 https://trial.medpath.com/news/newron-initiates-enigma-trs-2-phase-iii-trial-for-treatment-resistant-schizophrenia-in-us 2025-12-08T13:26:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/newron-initiates-enigma-trs-2-phase-iii-trial-for-treatment-resistant-schizophrenia-in-us 2025-12-08T13:26:54+00:00 hourly 0.9 https://trial.medpath.com/news/genmab-discontinues-phase-iii-lung-cancer-bispecific-antibody-acasunlimab-to-focus-on-late-stage-pipeline 2025-12-08T13:26:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genmab-discontinues-phase-iii-lung-cancer-bispecific-antibody-acasunlimab-to-focus-on-late-stage-pipeline 2025-12-08T13:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/poolbeg-pharma-s-polb-001-takes-center-stage-in-ps3-4-million-crs-prevention-research-programme 2025-12-08T13:26:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/poolbeg-pharma-s-polb-001-takes-center-stage-in-ps3-4-million-crs-prevention-research-programme 2025-12-08T13:26:39+00:00 hourly 0.9 https://trial.medpath.com/news/anuh-pharma-secures-european-regulatory-approval-for-veterinary-antibiotic-sulfadimethoxine 2025-12-08T13:26:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anuh-pharma-secures-european-regulatory-approval-for-veterinary-antibiotic-sulfadimethoxine 2025-12-08T13:26:20+00:00 hourly 0.9 https://trial.medpath.com/news/cloudbreak-therapeutics-advances-cbt-004-to-phase-3-trials-following-successful-fda-meeting-for-vascularized-pinguecula-treatment 2025-12-08T09:29:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cloudbreak-therapeutics-advances-cbt-004-to-phase-3-trials-following-successful-fda-meeting-for-vascularized-pinguecula-treatment 2025-12-08T09:29:46+00:00 hourly 0.9 https://trial.medpath.com/news/aprea-therapeutics-secures-3-1-million-private-placement-to-advance-cancer-targeting-drug-development 2025-12-08T09:29:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aprea-therapeutics-secures-3-1-million-private-placement-to-advance-cancer-targeting-drug-development 2025-12-08T09:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/sensorion-s-gene-therapy-sens-501-shows-early-efficacy-signals-in-pediatric-congenital-deafness-trial 2025-12-08T09:28:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sensorion-s-gene-therapy-sens-501-shows-early-efficacy-signals-in-pediatric-congenital-deafness-trial 2025-12-08T09:28:21+00:00 hourly 0.9 https://trial.medpath.com/news/fanss-study-demonstrates-promising-lung-cancer-detection-rates-in-non-smoking-asian-women 2025-12-08T09:28:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fanss-study-demonstrates-promising-lung-cancer-detection-rates-in-non-smoking-asian-women 2025-12-08T09:28:13+00:00 hourly 0.9 https://trial.medpath.com/news/victorian-researchers-develop-rna-prime-editing-therapy-for-fanconi-anemia-and-rare-blood-disorders 2025-12-08T09:27:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/victorian-researchers-develop-rna-prime-editing-therapy-for-fanconi-anemia-and-rare-blood-disorders 2025-12-08T09:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/epiendo-s-glasmacinal-shows-promise-in-first-copd-clinical-trial-reduces-neutrophilic-inflammation-without-antimicrobial-resistance 2025-12-08T09:26:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epiendo-s-glasmacinal-shows-promise-in-first-copd-clinical-trial-reduces-neutrophilic-inflammation-without-antimicrobial-resistance 2025-12-08T09:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-s-fenfluramine-shows-significant-seizure-reduction-in-phase-3-trial-for-cdkl5-deficiency-disorder 2025-12-08T09:26:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-s-fenfluramine-shows-significant-seizure-reduction-in-phase-3-trial-for-cdkl5-deficiency-disorder 2025-12-08T09:26:10+00:00 hourly 0.9 https://trial.medpath.com/news/iaso-bio-s-car-t-therapy-shows-93-8-complete-response-rate-in-high-risk-multiple-myeloma-patients 2025-12-08T09:25:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iaso-bio-s-car-t-therapy-shows-93-8-complete-response-rate-in-high-risk-multiple-myeloma-patients 2025-12-08T09:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/puretech-s-deupirfenidone-receives-fda-backing-for-phase-3-trial-in-idiopathic-pulmonary-fibrosis 2025-12-08T09:25:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/puretech-s-deupirfenidone-receives-fda-backing-for-phase-3-trial-in-idiopathic-pulmonary-fibrosis 2025-12-08T09:25:18+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-s-vabysmo-demonstrates-sustained-vision-improvements-in-48-week-angioid-streaks-trial 2025-12-08T09:24:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-s-vabysmo-demonstrates-sustained-vision-improvements-in-48-week-angioid-streaks-trial 2025-12-08T09:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-internalizes-hyaluronidase-based-subcutaneous-formulation-technology-to-expand-biosimilar-pipeline 2025-12-08T05:27:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-internalizes-hyaluronidase-based-subcutaneous-formulation-technology-to-expand-biosimilar-pipeline 2025-12-08T05:27:56+00:00 hourly 0.9 https://trial.medpath.com/news/lower-dose-ipilimumab-shows-superior-efficacy-and-safety-in-advanced-melanoma-treatment 2025-12-08T05:27:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lower-dose-ipilimumab-shows-superior-efficacy-and-safety-in-advanced-melanoma-treatment 2025-12-08T05:27:47+00:00 hourly 0.9 https://trial.medpath.com/news/imugene-receives-fda-support-for-azer-cel-car-t-therapy-registration-pathway-in-lymphoma 2025-12-08T05:27:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imugene-receives-fda-support-for-azer-cel-car-t-therapy-registration-pathway-in-lymphoma 2025-12-08T05:27:12+00:00 hourly 0.9 https://trial.medpath.com/news/ghit-fund-invests-460000-in-novel-mpox-diagnostic-test-development-to-address-african-outbreak 2025-12-08T05:26:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ghit-fund-invests-460000-in-novel-mpox-diagnostic-test-development-to-address-african-outbreak 2025-12-08T05:26:48+00:00 hourly 0.9 https://trial.medpath.com/news/chimeric-therapeutics-receives-fda-orphan-drug-designation-for-chm-cdh17-car-t-therapy-in-gastric-cancer 2025-12-08T05:26:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chimeric-therapeutics-receives-fda-orphan-drug-designation-for-chm-cdh17-car-t-therapy-in-gastric-cancer 2025-12-08T05:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/leads-biolabs-lbl-034-demonstrates-82-5-response-rate-in-relapsed-refractory-multiple-myeloma-at-ash-2025 2025-12-08T05:25:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leads-biolabs-lbl-034-demonstrates-82-5-response-rate-in-relapsed-refractory-multiple-myeloma-at-ash-2025 2025-12-08T05:25:50+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-s-trispecific-antibody-ibi3003-shows-83-3-response-rate-in-heavily-pretreated-multiple-myeloma-patients 2025-12-08T05:24:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovent-s-trispecific-antibody-ibi3003-shows-83-3-response-rate-in-heavily-pretreated-multiple-myeloma-patients 2025-12-08T05:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/iktos-secures-eur1-billion-partnership-with-servier-to-bridge-ai-drug-discovery-with-wet-lab-operations 2025-12-08T03:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iktos-secures-eur1-billion-partnership-with-servier-to-bridge-ai-drug-discovery-with-wet-lab-operations 2025-12-08T03:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/hutchmed-secures-continued-nrdl-coverage-for-three-cancer-drugs-and-gains-commercial-insurance-access-for-tazemetostat-in-china 2025-12-08T01:30:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hutchmed-secures-continued-nrdl-coverage-for-three-cancer-drugs-and-gains-commercial-insurance-access-for-tazemetostat-in-china 2025-12-08T01:30:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-pitolisant-label-to-include-cataplexy-treatment-in-pediatric-narcolepsy-patients 2025-12-08T01:29:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-pitolisant-label-to-include-cataplexy-treatment-in-pediatric-narcolepsy-patients 2025-12-08T01:29:40+00:00 hourly 0.9 https://trial.medpath.com/news/dual-bispecific-antibody-combination-achieves-79-response-rate-in-relapsed-refractory-multiple-myeloma-with-extramedullary-disease 2025-12-08T01:29:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-bispecific-antibody-combination-achieves-79-response-rate-in-relapsed-refractory-multiple-myeloma-with-extramedullary-disease 2025-12-08T01:29:37+00:00 hourly 0.9 https://trial.medpath.com/news/miltenyi-s-dual-target-car-t-therapy-shows-superior-efficacy-in-pivotal-trial-for-relapsed-large-b-cell-lymphoma 2025-12-08T01:29:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/miltenyi-s-dual-target-car-t-therapy-shows-superior-efficacy-in-pivotal-trial-for-relapsed-large-b-cell-lymphoma 2025-12-08T01:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/smart-stop-trial-shows-targeted-therapy-first-strategy-reduces-chemotherapy-need-in-large-b-cell-lymphoma 2025-12-08T01:29:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smart-stop-trial-shows-targeted-therapy-first-strategy-reduces-chemotherapy-need-in-large-b-cell-lymphoma 2025-12-08T01:29:18+00:00 hourly 0.9 https://trial.medpath.com/news/lynozyfic-monotherapy-shows-promising-efficacy-in-newly-diagnosed-multiple-myeloma-patients 2025-12-08T01:27:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lynozyfic-monotherapy-shows-promising-efficacy-in-newly-diagnosed-multiple-myeloma-patients 2025-12-08T01:27:24+00:00 hourly 0.9 https://trial.medpath.com/news/structure-therapeutics-to-release-pivotal-data-for-oral-glp-1-obesity-drug-aleniglipron 2025-12-08T01:26:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/structure-therapeutics-to-release-pivotal-data-for-oral-glp-1-obesity-drug-aleniglipron 2025-12-08T01:26:58+00:00 hourly 0.9 https://trial.medpath.com/news/triple-therapy-combination-shows-promise-for-rare-blood-cancer-bpdcn-with-high-response-rates 2025-12-08T01:26:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triple-therapy-combination-shows-promise-for-rare-blood-cancer-bpdcn-with-high-response-rates 2025-12-08T01:26:46+00:00 hourly 0.9 https://trial.medpath.com/news/telix-pharmaceuticals-advances-prostact-global-phase-3-trial-with-first-patient-dosed-in-randomized-expansion 2025-12-08T01:26:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telix-pharmaceuticals-advances-prostact-global-phase-3-trial-with-first-patient-dosed-in-randomized-expansion 2025-12-08T01:26:43+00:00 hourly 0.9 https://trial.medpath.com/news/lyell-s-ronde-cel-shows-93-response-rate-in-large-b-cell-lymphoma-with-enhanced-safety-profile 2025-12-08T01:25:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lyell-s-ronde-cel-shows-93-response-rate-in-large-b-cell-lymphoma-with-enhanced-safety-profile 2025-12-08T01:25:39+00:00 hourly 0.9 https://trial.medpath.com/news/grace-and-molecule-one-partner-to-revolutionize-peptide-manufacturing-with-ai-driven-synthesis-platform 2025-12-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grace-and-molecule-one-partner-to-revolutionize-peptide-manufacturing-with-ai-driven-synthesis-platform 2025-12-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/faron-pharmaceuticals-advances-bexmarilimab-with-new-phase-ii-trial-and-promising-ash-data-in-blood-cancers 2025-12-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faron-pharmaceuticals-advances-bexmarilimab-with-new-phase-ii-trial-and-promising-ash-data-in-blood-cancers 2025-12-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/isatuximab-based-therapy-shows-sustained-efficacy-across-age-groups-in-transplant-ineligible-multiple-myeloma 2025-12-07T21:30:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/isatuximab-based-therapy-shows-sustained-efficacy-across-age-groups-in-transplant-ineligible-multiple-myeloma 2025-12-07T21:30:03+00:00 hourly 0.9 https://trial.medpath.com/news/aop-health-presents-new-clinical-data-for-ropeginterferon-alfa-2b-in-rare-blood-cancers-at-ash-2025 2025-12-07T21:29:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aop-health-presents-new-clinical-data-for-ropeginterferon-alfa-2b-in-rare-blood-cancers-at-ash-2025 2025-12-07T21:29:28+00:00 hourly 0.9 https://trial.medpath.com/news/dyne-therapeutics-stock-plunges-17-following-300-million-secondary-offering-despite-dmd-trial-success 2025-12-07T21:29:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyne-therapeutics-stock-plunges-17-following-300-million-secondary-offering-despite-dmd-trial-success 2025-12-07T21:29:19+00:00 hourly 0.9 https://trial.medpath.com/news/cenobamate-demonstrates-sustained-efficacy-in-asian-and-chinese-patients-with-focal-seizures 2025-12-07T21:27:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cenobamate-demonstrates-sustained-efficacy-in-asian-and-chinese-patients-with-focal-seizures 2025-12-07T21:27:57+00:00 hourly 0.9 https://trial.medpath.com/news/msd-pharma-receives-conditional-approval-for-phase-iii-trial-of-sacituzumab-tirumotecan-in-india 2025-12-07T21:27:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/msd-pharma-receives-conditional-approval-for-phase-iii-trial-of-sacituzumab-tirumotecan-in-india 2025-12-07T21:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-biosciences-completes-enrollment-in-pivotal-uveal-melanoma-trial-advances-novel-adc-program 2025-12-07T21:27:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ideaya-biosciences-completes-enrollment-in-pivotal-uveal-melanoma-trial-advances-novel-adc-program 2025-12-07T21:27:39+00:00 hourly 0.9 https://trial.medpath.com/news/five-day-azacitidine-regimen-shows-superior-survival-outcomes-in-lower-risk-mds-patients 2025-12-07T21:26:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-day-azacitidine-regimen-shows-superior-survival-outcomes-in-lower-risk-mds-patients 2025-12-07T21:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/hemgenix-gene-therapy-shows-sustained-five-year-efficacy-in-hemophilia-b-patients 2025-12-07T21:26:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemgenix-gene-therapy-shows-sustained-five-year-efficacy-in-hemophilia-b-patients 2025-12-07T21:26:07+00:00 hourly 0.9 https://trial.medpath.com/news/secura-bio-reports-sustained-efficacy-of-duvelisib-in-heavily-pretreated-peripheral-t-cell-lymphoma-patients 2025-12-07T17:29:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/secura-bio-reports-sustained-efficacy-of-duvelisib-in-heavily-pretreated-peripheral-t-cell-lymphoma-patients 2025-12-07T17:29:45+00:00 hourly 0.9 https://trial.medpath.com/news/zai-lab-secures-reimbursement-renewal-for-three-key-therapies-in-china-s-2025-national-drug-list 2025-12-07T17:28:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zai-lab-secures-reimbursement-renewal-for-three-key-therapies-in-china-s-2025-national-drug-list 2025-12-07T17:28:12+00:00 hourly 0.9 https://trial.medpath.com/news/cellcentric-s-inobrodib-shows-60-75-response-rates-in-heavily-pretreated-multiple-myeloma-patients 2025-12-07T17:25:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellcentric-s-inobrodib-shows-60-75-response-rates-in-heavily-pretreated-multiple-myeloma-patients 2025-12-07T17:25:23+00:00 hourly 0.9 https://trial.medpath.com/news/alx-oncology-s-evorpacept-combination-achieves-92-complete-response-rate-in-frontline-indolent-non-hodgkin-lymphoma-trial 2025-12-07T17:25:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alx-oncology-s-evorpacept-combination-achieves-92-complete-response-rate-in-frontline-indolent-non-hodgkin-lymphoma-trial 2025-12-07T17:25:12+00:00 hourly 0.9 https://trial.medpath.com/news/bioinvent-s-bi-1808-shows-46-response-rate-in-cutaneous-t-cell-lymphoma-phase-2a-trial 2025-12-07T17:25:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioinvent-s-bi-1808-shows-46-response-rate-in-cutaneous-t-cell-lymphoma-phase-2a-trial 2025-12-07T17:25:06+00:00 hourly 0.9 https://trial.medpath.com/news/prime-medicine-reports-first-in-human-prime-editing-success-for-chronic-granulomatous-disease-in-nejm 2025-12-07T17:25:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prime-medicine-reports-first-in-human-prime-editing-success-for-chronic-granulomatous-disease-in-nejm 2025-12-07T17:25:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-incyte-s-first-in-class-mutcalr-targeted-antibody-for-essential-thrombocythemia 2025-12-07T17:24:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-incyte-s-first-in-class-mutcalr-targeted-antibody-for-essential-thrombocythemia 2025-12-07T17:24:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-incyte-s-inca033989-for-rare-blood-cancer 2025-12-07T17:24:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-incyte-s-inca033989-for-rare-blood-cancer 2025-12-07T17:24:18+00:00 hourly 0.9 https://trial.medpath.com/news/rigel-s-r289-shows-promise-in-lower-risk-mds-with-33-transfusion-independence-rate-at-ash-2025 2025-12-07T17:23:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rigel-s-r289-shows-promise-in-lower-risk-mds-with-33-transfusion-independence-rate-at-ash-2025 2025-12-07T17:23:42+00:00 hourly 0.9 https://trial.medpath.com/news/formosa-pharmaceuticals-expands-global-reach-of-fda-approved-eye-surgery-treatment-through-asean-partnership 2025-12-07T13:30:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formosa-pharmaceuticals-expands-global-reach-of-fda-approved-eye-surgery-treatment-through-asean-partnership 2025-12-07T13:30:32+00:00 hourly 0.9 https://trial.medpath.com/news/carsgen-s-car-t-therapy-zevor-cel-gains-coverage-under-china-s-new-commercial-health-insurance-catalogue 2025-12-07T13:29:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carsgen-s-car-t-therapy-zevor-cel-gains-coverage-under-china-s-new-commercial-health-insurance-catalogue 2025-12-07T13:29:44+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-2025-national-drug-list-adds-114-medicines-with-historic-commercial-insurance-breakthrough 2025-12-07T13:28:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-2025-national-drug-list-adds-114-medicines-with-historic-commercial-insurance-breakthrough 2025-12-07T13:28:53+00:00 hourly 0.9 https://trial.medpath.com/news/china-expands-national-medical-insurance-coverage-with-114-new-drugs-including-50-innovative-pharmaceuticals 2025-12-07T09:26:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-expands-national-medical-insurance-coverage-with-114-new-drugs-including-50-innovative-pharmaceuticals 2025-12-07T09:26:53+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-approves-levim-lifetech-s-phase-i-iii-trial-for-teriparatide-biosimilar-in-osteoporosis 2025-12-07T09:26:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-approves-levim-lifetech-s-phase-i-iii-trial-for-teriparatide-biosimilar-in-osteoporosis 2025-12-07T09:26:47+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-biosciences-initiates-phase-2a-trial-for-schizophrenia-treatment-following-depression-drug-setback 2025-12-07T09:26:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocrine-biosciences-initiates-phase-2a-trial-for-schizophrenia-treatment-following-depression-drug-setback 2025-12-07T09:26:35+00:00 hourly 0.9 https://trial.medpath.com/news/akeso-achieves-complete-nrdl-coverage-for-five-innovative-drugs-in-china-including-first-in-class-bispecifics 2025-12-07T09:26:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akeso-achieves-complete-nrdl-coverage-for-five-innovative-drugs-in-china-including-first-in-class-bispecifics 2025-12-07T09:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-secures-nrdl-inclusion-for-seven-innovative-therapies-expanding-access-to-cancer-and-rare-disease-treatments-in-china 2025-12-07T09:26:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovent-secures-nrdl-inclusion-for-seven-innovative-therapies-expanding-access-to-cancer-and-rare-disease-treatments-in-china 2025-12-07T09:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/csl-seqirus-opens-1-billion-cell-based-vaccine-manufacturing-facility-in-melbourne 2025-12-07T05:26:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/csl-seqirus-opens-1-billion-cell-based-vaccine-manufacturing-facility-in-melbourne 2025-12-07T05:26:55+00:00 hourly 0.9 https://trial.medpath.com/news/ctdna-testing-outperforms-pet-ct-in-predicting-lymphoma-patient-outcomes 2025-12-07T05:26:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ctdna-testing-outperforms-pet-ct-in-predicting-lymphoma-patient-outcomes 2025-12-07T05:26:46+00:00 hourly 0.9 https://trial.medpath.com/news/akari-therapeutics-initiates-gmp-manufacturing-for-novel-adc-aktx-101-with-wuxi-xdc-partnership 2025-12-07T03:24:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akari-therapeutics-initiates-gmp-manufacturing-for-novel-adc-aktx-101-with-wuxi-xdc-partnership 2025-12-07T03:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/once-weekly-oral-hiv-therapy-shows-promise-in-phase-2-trial-maintaining-viral-suppression-through-48-weeks 2025-12-07T01:30:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/once-weekly-oral-hiv-therapy-shows-promise-in-phase-2-trial-maintaining-viral-suppression-through-48-weeks 2025-12-07T01:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/axatilimab-monthly-dosing-shows-promise-for-chronic-gvhd-treatment-convenience 2025-12-07T01:29:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axatilimab-monthly-dosing-shows-promise-for-chronic-gvhd-treatment-convenience 2025-12-07T01:29:42+00:00 hourly 0.9 https://trial.medpath.com/news/star-therapeutics-reports-promising-phase-1-2-data-for-vga039-in-von-willebrand-disease-showing-73-100-reduction-in-bleeding-episodes 2025-12-07T01:26:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/star-therapeutics-reports-promising-phase-1-2-data-for-vga039-in-von-willebrand-disease-showing-73-100-reduction-in-bleeding-episodes 2025-12-07T01:26:50+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-and-oncoc4-report-54-reduction-in-death-risk-with-gotistobart-in-advanced-squamous-lung-cancer 2025-12-07T01:26:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biontech-and-oncoc4-report-54-reduction-in-death-risk-with-gotistobart-in-advanced-squamous-lung-cancer 2025-12-07T01:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/zenocutuzumab-shows-superior-efficacy-in-treatment-naive-nrg1-nsclc-patients 2025-12-07T01:26:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zenocutuzumab-shows-superior-efficacy-in-treatment-naive-nrg1-nsclc-patients 2025-12-07T01:26:39+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-and-eisai-advance-leqembi-subcutaneous-formulation-with-china-regulatory-milestone 2025-12-07T00:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-and-eisai-advance-leqembi-subcutaneous-formulation-with-china-regulatory-milestone 2025-12-07T00:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-linked-to-12-higher-risk-of-chronic-cough-in-large-scale-study 2025-12-06T21:32:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-linked-to-12-higher-risk-of-chronic-cough-in-large-scale-study 2025-12-06T21:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-recalls-over-11000-bottles-of-blood-pressure-drug-due-to-cholesterol-medication-cross-contamination 2025-12-06T21:32:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-recalls-over-11000-bottles-of-blood-pressure-drug-due-to-cholesterol-medication-cross-contamination 2025-12-06T21:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/iv-iron-treatment-improves-survival-in-anemic-patients-with-acute-bacterial-infections-large-scale-study-shows 2025-12-06T21:32:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iv-iron-treatment-improves-survival-in-anemic-patients-with-acute-bacterial-infections-large-scale-study-shows 2025-12-06T21:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/elranatamab-plus-iberdomide-combination-achieves-95-5-response-rate-in-relapsed-refractory-multiple-myeloma 2025-12-06T21:31:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elranatamab-plus-iberdomide-combination-achieves-95-5-response-rate-in-relapsed-refractory-multiple-myeloma 2025-12-06T21:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/disc-medicine-s-disc-0974-shows-promising-results-for-myelofibrosis-anemia-in-phase-2-trial 2025-12-06T21:30:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/disc-medicine-s-disc-0974-shows-promising-results-for-myelofibrosis-anemia-in-phase-2-trial 2025-12-06T21:30:15+00:00 hourly 0.9 https://trial.medpath.com/news/novel-btk-degrader-bgb-16673-demonstrates-85-response-rate-in-heavily-pretreated-cll-sll-patients 2025-12-06T21:30:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-btk-degrader-bgb-16673-demonstrates-85-response-rate-in-heavily-pretreated-cll-sll-patients 2025-12-06T21:30:12+00:00 hourly 0.9 https://trial.medpath.com/news/ash-2025-reveals-critical-gaps-in-sickle-cell-emergency-care-and-promising-gene-therapy-advances 2025-12-06T21:29:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ash-2025-reveals-critical-gaps-in-sickle-cell-emergency-care-and-promising-gene-therapy-advances 2025-12-06T21:29:52+00:00 hourly 0.9 https://trial.medpath.com/news/prelude-therapeutics-unveils-novel-jak2v617f-selective-inhibitor-and-mcalr-targeted-therapy-for-myeloproliferative-neoplasms 2025-12-06T21:29:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prelude-therapeutics-unveils-novel-jak2v617f-selective-inhibitor-and-mcalr-targeted-therapy-for-myeloproliferative-neoplasms 2025-12-06T21:29:50+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-s-bexicaserin-shows-sustained-seizure-reduction-in-rare-childhood-epilepsies-after-two-years-of-treatment 2025-12-06T21:29:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-s-bexicaserin-shows-sustained-seizure-reduction-in-rare-childhood-epilepsies-after-two-years-of-treatment 2025-12-06T21:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-endrad-study-shows-non-tbi-conditioning-maintains-efficacy-in-pediatric-b-all-transplant 2025-12-06T21:28:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-2-endrad-study-shows-non-tbi-conditioning-maintains-efficacy-in-pediatric-b-all-transplant 2025-12-06T21:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/kite-s-anito-cel-shows-96-response-rate-in-pivotal-multiple-myeloma-trial-supporting-2026-launch-plans 2025-12-06T21:28:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kite-s-anito-cel-shows-96-response-rate-in-pivotal-multiple-myeloma-trial-supporting-2026-launch-plans 2025-12-06T21:28:54+00:00 hourly 0.9 https://trial.medpath.com/news/natera-acquires-foresight-diagnostics-for-275-million-to-advance-molecular-residual-disease-detection 2025-12-06T21:27:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natera-acquires-foresight-diagnostics-for-275-million-to-advance-molecular-residual-disease-detection 2025-12-06T21:27:36+00:00 hourly 0.9 https://trial.medpath.com/news/sapablursen-shows-promising-results-in-phase-2a-trial-for-polycythemia-vera-significantly-reducing-phlebotomy-burden 2025-12-06T21:26:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sapablursen-shows-promising-results-in-phase-2a-trial-for-polycythemia-vera-significantly-reducing-phlebotomy-burden 2025-12-06T21:26:08+00:00 hourly 0.9 https://trial.medpath.com/news/states-push-for-fda-approval-of-ibogaine-clinical-trials-to-treat-ptsd-and-opioid-addiction 2025-12-06T21:25:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/states-push-for-fda-approval-of-ibogaine-clinical-trials-to-treat-ptsd-and-opioid-addiction 2025-12-06T21:25:45+00:00 hourly 0.9 https://trial.medpath.com/news/measurable-residual-disease-validated-as-strong-predictor-of-survival-in-aml-patients 2025-12-06T21:25:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/measurable-residual-disease-validated-as-strong-predictor-of-survival-in-aml-patients 2025-12-06T21:25:39+00:00 hourly 0.9 https://trial.medpath.com/news/verona-trial-shows-mixed-results-for-venetoclax-azacitidine-combination-in-high-risk-mds 2025-12-06T21:25:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verona-trial-shows-mixed-results-for-venetoclax-azacitidine-combination-in-high-risk-mds 2025-12-06T21:25:37+00:00 hourly 0.9 https://trial.medpath.com/news/orca-bio-reports-promising-results-for-orca-t-cell-therapy-in-older-blood-cancer-patients-at-ash-2025 2025-12-06T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orca-bio-reports-promising-results-for-orca-t-cell-therapy-in-older-blood-cancer-patients-at-ash-2025 2025-12-06T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/lisaftoclax-demonstrates-62-5-response-rate-in-btk-refractory-cll-sll-patients 2025-12-06T17:36:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lisaftoclax-demonstrates-62-5-response-rate-in-btk-refractory-cll-sll-patients 2025-12-06T17:36:11+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-indian-study-validates-ai-enhanced-smile-laser-technology-for-myopia-correction 2025-12-06T17:35:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-scale-indian-study-validates-ai-enhanced-smile-laser-technology-for-myopia-correction 2025-12-06T17:35:08+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-divests-815-million-biocon-biologics-stake-to-accelerate-biosimilars-market-re-entry 2025-12-06T17:33:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viatris-divests-815-million-biocon-biologics-stake-to-accelerate-biosimilars-market-re-entry 2025-12-06T17:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/beam-therapeutics-reports-promising-long-term-data-for-base-edited-sickle-cell-therapy-risto-cel 2025-12-06T17:32:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beam-therapeutics-reports-promising-long-term-data-for-base-edited-sickle-cell-therapy-risto-cel 2025-12-06T17:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/kala-bio-completes-10-million-funding-round-to-advance-rare-eye-disease-therapies 2025-12-06T17:31:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kala-bio-completes-10-million-funding-round-to-advance-rare-eye-disease-therapies 2025-12-06T17:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/tirzepatide-demonstrates-94-reduction-in-type-2-diabetes-risk-in-landmark-prevention-trial 2025-12-06T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tirzepatide-demonstrates-94-reduction-in-type-2-diabetes-risk-in-landmark-prevention-trial 2025-12-06T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/large-french-study-links-mrna-covid-19-vaccination-to-25-reduction-in-long-term-mortality 2025-12-06T17:29:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-french-study-links-mrna-covid-19-vaccination-to-25-reduction-in-long-term-mortality 2025-12-06T17:29:46+00:00 hourly 0.9 https://trial.medpath.com/news/io-therapeutics-reports-synergistic-activity-of-rxr-agonist-irx4204-with-car-t-therapy-in-multiple-myeloma 2025-12-06T17:29:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/io-therapeutics-reports-synergistic-activity-of-rxr-agonist-irx4204-with-car-t-therapy-in-multiple-myeloma 2025-12-06T17:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/sync-t-therapy-shows-54-complete-bone-metastasis-resolution-in-phase-1-prostate-cancer-trial 2025-12-06T17:28:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sync-t-therapy-shows-54-complete-bone-metastasis-resolution-in-phase-1-prostate-cancer-trial 2025-12-06T17:28:35+00:00 hourly 0.9 https://trial.medpath.com/news/arvinas-reports-promising-preclinical-data-for-arv-393-and-glofitamab-combination-in-b-cell-lymphoma 2025-12-06T17:28:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arvinas-reports-promising-preclinical-data-for-arv-393-and-glofitamab-combination-in-b-cell-lymphoma 2025-12-06T17:28:30+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-gene-therapy-implementation-shows-promise-for-blood-disorders-despite-timeline-challenges 2025-12-06T17:27:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-gene-therapy-implementation-shows-promise-for-blood-disorders-despite-timeline-challenges 2025-12-06T17:27:14+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-s-crispr-therapy-casgevy-shows-promise-in-children-as-young-as-5-with-blood-disorders 2025-12-06T17:26:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-s-crispr-therapy-casgevy-shows-promise-in-children-as-young-as-5-with-blood-disorders 2025-12-06T17:26:32+00:00 hourly 0.9 https://trial.medpath.com/news/atara-biotherapeutics-approaches-critical-fda-decision-for-tab-cel-as-company-implements-strategic-restructuring 2025-12-06T17:26:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atara-biotherapeutics-approaches-critical-fda-decision-for-tab-cel-as-company-implements-strategic-restructuring 2025-12-06T17:26:29+00:00 hourly 0.9 https://trial.medpath.com/news/cqdm-awards-500000-to-develop-fut8-inhibitors-for-enhanced-cancer-antibody-therapies 2025-12-06T17:25:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cqdm-awards-500000-to-develop-fut8-inhibitors-for-enhanced-cancer-antibody-therapies 2025-12-06T17:25:25+00:00 hourly 0.9 https://trial.medpath.com/news/realta-reports-promising-phase-2-results-for-pegtarazimod-in-steroid-refractory-acute-graft-versus-host-disease 2025-12-06T17:25:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/realta-reports-promising-phase-2-results-for-pegtarazimod-in-steroid-refractory-acute-graft-versus-host-disease 2025-12-06T17:25:23+00:00 hourly 0.9 https://trial.medpath.com/news/deucravacitinib-shows-efficacy-in-psoriasis-patients-who-failed-apremilast-treatment 2025-12-06T17:25:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deucravacitinib-shows-efficacy-in-psoriasis-patients-who-failed-apremilast-treatment 2025-12-06T17:25:20+00:00 hourly 0.9 https://trial.medpath.com/news/carvykti-shows-durable-treatment-free-remissions-at-2-5-years-in-earlier-line-multiple-myeloma 2025-12-06T17:25:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carvykti-shows-durable-treatment-free-remissions-at-2-5-years-in-earlier-line-multiple-myeloma 2025-12-06T17:25:18+00:00 hourly 0.9 https://trial.medpath.com/news/nmdp-access-trial-shows-80-survival-with-mismatched-donor-transplants-expanding-access-for-blood-cancer-patients 2025-12-06T17:25:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nmdp-access-trial-shows-80-survival-with-mismatched-donor-transplants-expanding-access-for-blood-cancer-patients 2025-12-06T17:25:15+00:00 hourly 0.9 https://trial.medpath.com/news/rusfertide-demonstrates-sustained-efficacy-in-52-week-polycythemia-vera-study-supporting-regulatory-filing 2025-12-06T17:25:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rusfertide-demonstrates-sustained-efficacy-in-52-week-polycythemia-vera-study-supporting-regulatory-filing 2025-12-06T17:25:10+00:00 hourly 0.9